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ABSTRACT
There is much pharmacological evidence that suggests the existence of multiple 6- 
opioid receptors. However to date only one gene encoding for the receptor and no 
functional splice variants of the Ô-opioid receptor have been reported. It has been 
suggested that ô-opioid receptors that exist in different environments or are differently 
coupled to signalling pathways could be an explanation for the pharmacological data 
that suggest ô-opioid receptor subtypes. To address the influence of G-protein 
coupling of the receptor on ligand binding, the current study uses quantitative 
autoradiography and homogenate binding to characterise the selectivity of four Ô- 
opioid receptor ligands for the G-protein coupled and uncoupled states of the ô-opioid 
receptor. Quantitative autoradiography was also carried out in the brains of mice 
lacking the p-opioid receptor to determine the effect the absence of the p-opioid 
receptor has on the G-protein coupling of the Ô-opioid receptor. In addition 
microphysiometry and isolated tissue pharmacology have been utilised to further 
characterise the functional responses of naltrindole and RATGLU at the ô-opioid 
receptor. SNC-121, a selective ô-opioid receptor agonist has previously been reported 
to have both an atypical binding profile at Ô-opioid receptors and a non-opioid binding 
site. To address this issue the binding of [^H]SNC-121 in the brains of mice lacking 
the ô-opioid receptor was determined using autoradiography. The studies described in 
this thesis demonstrate that some Ô-opioid receptors in some discrete, predominantly 
non-cortical brain regions become uncoupled from G-proteins in the absence of p.- 
opioid receptors. In addition this study demonstrates that [^H]SNC-121 binds to a 
receptor which is not an opioid receptor but which is localised to brain regions 
predominantly expressing high levels of ô-opioid receptors. This study also provides 
further evidence for the existence of a physically interacting complex between ô and 
p-opioid receptors and further characterises the non-opioid binding of [^H]SNC-121.
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Chapter 1
Introduction
1. INTRODUCTION
1.1. Historical Background
Opium is obtained from the dried sap of the unripe seed pods of Papaver somniferum. For 
many centuries opium has been used for its medicinal properties, notably as an analgesic, a 
sedative and an anti-diarrhoeal agent. Opium also causes euphoria, a property that has led 
to its use for recreational purposes. There are several undesirable side effects associated 
with the use of opium, these include nausea, vomiting, constipation and respiratory 
depression. In addition, as early as the 16^ Century chronic use of opium was recognised 
to result in tolerance and dependence. In 1803, pure morphine was isolated from opium by 
Sertümer, a German chemist, the structure of morphine was later elucidated (Fig 1.1). Raw 
opium contains approximately 10% morphine, a small amount of codeine and other related 
alkaloids (e.g. papaverine). Morphine was demonstrated to be the principle agent 
responsible for both the analgesic properties and for the undesirable side effects of opium, 
including the potential to cause both tolerance and dependence. One of the other opium 
constituents, codeine (methyl morphine) (Fig. 1.1) was shown to be a less potent analgesic, 
less addictive and to cause little respiratory depression compared to morphine. It was 
therefore apparent that small structural changes in the structure of morphine could 
drastically alter the effect of opiates. The hunt for a synthetic opioid that was efficacious 
but non-addictive was initiated. In 1898 heroin (diacetylmorphine) was synthesised, it was 
claimed that this compound was a more potent analgesic than morphine, but non-addictive. 
Heroin was later demonstrated to cause both tolerance and dependence, and consequently 
have as much potential for abuse as morphine. To date morphine remains the best 
analgesic available in medicine. The development of an analgesic drug that is as efficacious 
as morphine, but without side effects would clearly result in a significant clinical advance.
The effects of morphine and related opioids were suggested to be receptor mediated from 
the findings that demonstrated the analgesic properties of opioids were both structure-
N-CH
HO OH Morphine
N-CH,
OH Codeine
N-CH
OH
HO
Naloxone
Fig 1.1. Comparison of the structure of morphine and closely related analogues which 
display distinct pharmacological actions.
related and stereospecific (Portoghese, 1965). The existence of opioid receptors was first 
demonstrated in the early 1970’s, radiolabelled opioid ligands were shown to demonstrate 
high affinity, saturable and stereospecific binding in rat brain homogenates (Pert and 
Snyder, 1973; Simon et al, 1973; Terenius, 1973).
The existence of multiple opioid receptors was postulated after early observations showed 
different opioid agonists produced distinct physiological effects. The first definitive 
pharmacological evidence supporting the existence of multiple opioid receptors was 
reported by Martin and colleagues (1976). Morphine, ketocyclazocine, and SKF-10,047 
were each demonstrated to produce a different pharmacological syndrome in chronic spinal 
dog. Chronic administration of any one of the compounds induced tolerance to the drug, 
but not cross tolerance to either of the other two drugs. From these findings, Martin et al 
(1976) postulated the existence of three distinct types of opioid receptors and named them: 
|i, K, and a  associated with the three prototypical agonists, morphine, ketocyclazocine and 
SKF 10,047 respectively. To be classified as an opioid receptor mediated action, the effects 
of a drug must be reversible by naloxone, a potent opioid antagonist. More recent studies 
have demonstrated that the SKF-10,047 actions are not reversible by naloxone (see Zukin 
and Zukin, 1984), consequently the o-receptor is no longer considered an opioid receptor.
Lord and co-workers (1977) postulated the existence of a further opioid receptor to explain 
the in vitro activity of enkephalins (the first endogenous opioids to be discovered, see 
Section 1.2.) in the field stimulated mouse vas deferens. The existence of a 5-opioid 
receptor (for vas deferens) was suggested after enkephalins were shown to potently inhibit 
the electrically stimulated twitch of the mouse vas deferens, whilst only weakly inhibiting 
the isolated guinea-pig ileum twitch. In contrast, morphine the prototypical |i-opioid 
receptor agonist had higher potency at the guinea-pig ileum than the vas deferens. Further 
support for the existence of a 5-opioid receptor distinct to the established p.-opioid receptors
was provided by competition binding studies with morphine and enkephalins in guinea pig 
brain (Chang and Cuatrecasas, 1979).
The existence of three subtypes of opioid receptors was finally confirmed by the cloning of 
three genes each encoding one of the receptors. In 1992, the mouse ô-opioid receptor 
cDNA was successfully cloned by two groups working independently (Evans et a l, 1992; 
Kieffer e/ al, 1992). The cloning of the mouse \l- and K-opioid receptors quickly followed 
the cloning of the mouse ô-opioid receptor. Rat, p. (Chen et al, 1993), Ô (Fukuda et al, 
1993), and K-opioid receptors (Li et al, 1993) have now been cloned. The human p. (Wang 
et al, 1993), K (Mansson et al, 1994) and ô-opioid receptors (Knapp et al, 1994) have also 
been cloned. The receptor protein is highly conserved across the species, with each of the 
three receptors having more than 90% homology in the different mammalian species that 
have been cloned.
In addition to the three established opioid receptors, a receptor with a high degree of 
homology (>60%) to the opioid receptors was discovered during attempts at molecular 
cloning. This receptor has been termed the Opioid Receptor Like (ORL-1) (Mollereau et 
al, 1994). Two different groups reported the identification of the endogenous ligand for 
the ORL-1 receptor, the 17 amino acid peptide was termed nociceptin and orphanin FQ 
respectively (Meunier et a l, 1995; Reinscheid, 1995). In contrast to opioids the actions of 
nociceptin appeared to be anti-opioid in nature and naloxone insensitive. Despite the 
homology of the receptor proteins, the ORL-1 receptor has some distinct characteristics 
compared to the three classical opioid receptors (for a recent review of ORL-1 receptors 
and nociceptin the reader is referred to Calo et al, 2000; Harrison and Grandy, 2000).
A further opioid receptor has been postulated after [Met^Jenkephalin was demonstrated to 
act as a growth factor (Isayama et al, 1991; Linner et al, 1995). [Met^]enkephalin has 
been termed opioid growth factor (OGF) (Zagon and McLaughlin, 1993) and the receptor 
mediating this effect has since been cloned and characterised from rat (Zagon et a l, 1999)
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and human tissues (Zagon et al, 2000). This receptor was initially termed the Ç-opioid 
receptor and has since been renamed to the OGF receptor. The OGF receptor has been 
shown to have no homology with the classical opioid receptors and in contrast to either 
\L~, Ô- and K-opioid receptors, the OGF receptor is nuclear associated in both neural and 
non neural tissues. Despite the lack of homology of the receptor with the classical opioid 
receptors, the effects of peptides at the OGF receptor has been shown to be reversed by 
high concentrations of naloxone (Zagon and McLaughlin, 1993).
Further opioid receptors have been postulated from pharmacological studies but not as yet 
cloned. Such receptors include the e-receptor (Schulz et al, 1980; Nock et al, 1993), the t 
receptor (Oka et al, 1980) and the Z-receptor (Grevel and Sadee 1983). The evidence for 
these receptors is sparse and as yet they are not accepted as opioid receptors for 
classification purposes.
1.2. Endogenous Opioid System
The demonstration of the existence of opioid receptors led to the suggestion of an 
endogenous ligand or ligands to activate the receptors in vivo. In 1975 Hughes was the 
first to identify the existence of such a substance extracted from porcine brain.
The first members of this family to be characterised were two pentapeptides, [Met] and 
[Leu]-enkephalin (Table 1.1.). The enkephalins were first isolated from brain, where they 
have since been determined to be most abundant (Hughes et al, 1975). More than 20 
peptides have since been identified from the brain and the adrenal and pituitary glands. 
The endogenous opioid peptides originally made up three families, the enkephalins, the 
endorphins and the dynorphins. These peptides share a common N-terminal sequence 
(NH2-Tyr-Gly-Gly-Phe-Met/Leu) and derive from cleavage of large precursor proteins. 
The precursors have been identified to be translated from three different genes and are 
referred to as proopiomelanocortin (POMC), proenkephalin or prodynorphin (Rossier, 
1982; Young et al, 1983). POMC is the precursor for corticotrophin and a-melanotropin
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along with several endorphins (such as a-endorphin, y-endorphin and p-endorphin). 
Proenkephalin gives rise to four enkephalins (Met-enkephalin, Leu-enkephalin, Met- 
enkephalin-Arg-Gly-Leu and Met-enkephalin-Arg-Phe) and prodynorphin gives rise to 
several biologically active peptides (e.g. dynorphin(i.n) and (i.g), a-neoendorphin and 
neoendorphin) (see Table 1.1.) (for reviews on endogenous opioids see Hollt, 1983; Akil et 
al, 1984; Olson et al, 1991; Simon, 1991). >
Recently, two novel opioid peptides termed endomorphins have been isolated (Zadina et 
al , 1997) and the cloning of their precursor is awaited to confirm this as à hew farnily of 
endogenous opioids.
The endogenous opioid peptides show limited selectivity for the different receptors: p- 
endorphins bind most selectively to both the p.- and 6-opioid receptor, whilst enkephalins 
and dynorphins bind mainly 5- and K-opioid receptors respectively (Simon, 1991). The 
most recently discovered endomorphins have been demonstrated to be selective for the p,- 
opioid receptor (Zadina et al, 1997; Gong et al, 1998). In addition to their limited 
receptor selectivity, the endogenous peptides are unsuitable receptor probes due to their 
rapid degradation by proteases. In order to further elucidate the structure, regulation, 
function and distribution of the opioid-receptor subtypes, more selective and stable ligands 
for the opioid receptors were needed. Selective ligands ideally need to have an affinity of 
at least 2-3 orders of magnitude greater for the preferred subtype than for the either of the 
other subtypes (Goldstein and Naidu, 1989).
The focus of the current study is on the 6-opioid receptor. The remainder of this review 
will therefore be confined to discussion of 6-opioid receptor literature.
Table 1.1. Endogenous opioid precursors and their active products
Precursor Peptide products Amino acid sequence
Proenkephalin
[Met] enkephalin Tyr-Gly-Gly-Phe-Met
[Leu] enkephalin Tyr-Gly-Gly-Phe-Leu
[Met] enkephalin-Arg-Phe Tyr-Gly-Gly-Phe-Met-Arg-Phe
[Met] enkephalin-Arg-Gly-Leu Tyr-Gly-Gly-Phe-Met-Arg-Gly-Phe
Proopioimelanocortin
P-endorphin T yr-Gly-Gly-Phe-Leu-Thr-S er-Glu-Lys- S er- 
Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys- 
Asn-Ala-Ile-Ile-Lys-Lys-Asn-Ala-Tyr-Lys- 
Lys-Gly-Glu
a-endorphin T yr- Gly- Gly-Phe-Leu-Thr- S er- Glu-Ly s- S er- 
Gln-Thr-Pro-Leu-V al-Thr
y-endorphin Tyr-Gly-Gly-Phe-Leu-Thr-Ser-Glu-Lys-Ser-
Gln-Thr-Pro-Leu-Val-Thr-Leu
Prodynorphin
a-neo-endorphin Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro-Lys
p-neo-endorphin Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro
Dynorphin A(l-17) Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-
Lys-Leu-Lys-Trp-Asp-Asn-Glu
Dynorphin A(l-8) Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile
Dynorphin B Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe- 
Ly s-V al-V al-Thr
Unidentified precursor
Endomorphin I Tyr-Pro-Trp-Phe-NH2
Endomorphin II Tyr-Pro-Phe-Phe-NH2
1.3. Selective ligands for the 5-opioid receptor
1.3.1 5-Opioid receptor peptide agonists
As previously mentioned [Leu] enkephalin is a relatively selective ligand for the 5-opioid 
receptor, however like most endogenous peptides, it is rapidly degraded by tissue 
peptidases (McKnight et a l,  1983). The addition of a D-amino acid to [Leu]enkephalin 
analogues was proposed to prolong biological activity by preventing rapid enzymatic 
degradation. Belluzzi et al (1978) were the first to report such a peptide, [D-Ala^,D- 
Leu^]enkephalin (DADLE). Despite being resistant to protease degradation and a potent 5- 
opioid agonist, DADLE was also found to possess substantial p,-opioid receptor activity 
(Kosterlitz et aï., 1980). Greater 5-opioid selectivity was achieved by further modification 
of [Leu] enkephalin, the addition of threonine to the C-terminus and substitution with [D- 
Ser] at position 2 resulted in [D-Ser^,Leu^]enkephalin-threonine (DSLET) (Chang and 
Cuatrecasas, 1979; Gacel et a l,  1980). The addition of 0-tertiary butyl groups and further 
substitutions at position 2 of [Leu]enkephalin has lead to the development of other 5- 
selective peptides, including DSTUBLET (Tyr-D-Ser(OtBu)-Gly-Phe-Leu-Thr) and BUBU 
[Tyr-D-Ser(OtBu)-Gly-Phe-Leu-Thr(OtBu)] (Delay-Goyet et a l,  1986; De Vries et a l , 
1989). DSTUBLET was shown to have over 100 fold and BUBU 200-300 fold selectivity 
for 5 receptors compared to p,-opioid receptors.
The incorporation of conformational constraints in analogues of biologically active 
peptides is a well-known approach for enhancing receptor selectivity. Small peptides tend 
to have a high degree of flexibility allowing them to adopt multiple conformations, in turn 
this may lead to activation of several closely related receptor subtypes. Cyclisation of 
peptides promotes structural rigidity and therefore can increase selectivity of the peptides. 
The introduction of bis-penicillamine moieties to enkephalin analogues resulted in the 
development of cyclic peptides (e.g. [D-Pen^,D-Pen^]enkephalin (DPDPE) and [D-Pen^,L- 
Pen^] enkephalin (DPLPE)) with improved selectivity but not affinity for the 5-opioid 
receptor (Mosberg et al, 1983). Introduction of a halogen atom into position 4 of DPDPE
was shown to further enhance 5-opioid affinity (e.g. pCl-DPDPE) (Toth et al 1990) (Fig. 
1.2 .).
A peptide with high affinity for p.-opioid receptors was discovered in the skin of the South 
American frog Phyllomediisa sauvagei (Broccardo et al, 1981). The sequence of the 
precursor of dermorphin was later elucidated from a cDNA library (Richter et al, 1987). A 
major advancement in the development of selective and potent 5-opioid agonists came 
when a peptide related to dermorphin was found in the cDNA library. This peptide termed 
deltorphin was shown to bind to 5-opioid receptors at sub-nanomolar concentrations and to 
have more than 3000 fold selectivity for 5-opioid receptors compared to p.-receptors (Kreil 
et al, 1989). Two further 5-opioid selective peptides were isolated from the skin of 
Phyllomedusa bicolor (Erspamer et al, 1989). These two peptides, [D-Ala^]deltorphin I 
(deltorphin I) and [D-Ala^] deltorphin II (deltorphin II) consist of 7 amino acids and differ 
from each other only in the fourth amino acid (Fig. 1.2.). Deltorphin I and deltorphin II 
have both been shown to have 5-opioid receptor selectivity of more than 7000 fold. It has 
been reported that in general analogues of deltorphin I are more active at the 5-opioid 
receptor whereas deltorphin II and its analogues are more selective (Erspamer et al, 1989).
A series of deltorphin I and II conformationally constrained analogues were produced by 
modifying the side chains at position 3, 5 and 6 (Fig. 1.2.) causing changes in the 
hydrophobic and stereoelectronic properties of the ligands (Toth et al, 1997). Various 
substitutions were made into either position 3 (2-aminotetralin-2-carboxylic acid) and/or 
into position 5 and 6 (isoleucine) of the parent compounds. The resulting analogues were 
all delta-opioid agonists in the subnanomolar range as determined in the field stimulated 
mouse vas deferens. In addition to their potency some of the resulting analogues were 
found to be more than 10,000 fold selective for the 5-opioid receptor (e.g. (Ile-Ile) 
deltorphin I, (Ile-Ile)deltorphin II and ((S)-Atc-Asp-Ile-Ile) deltorphin II. One analogue 
((R)-Atc-Glu-Ile-Ile)deltorphin II (RATGLU) was shown to be more than 20,000 fold 
selective for 5-opioid receptors (Toth et a l, 1997).
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DPDPE H-Tyr-D-Pen-Gly-Phe-D-Pen-OH 
Deltorphin I H-Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2 
Deltorphin II H-Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 
RATGLU H-Tyr-D-Ala-(R)-Atc-Glu-Ile-Ile-Gly-NH2 
Fig. 1.2. Structures of the commonly used peptide 0-opioid receptor agonists
1.3.2. 5-Opioid receptor non-peptide agonists
Despite the production of potent and selective 5-opioid peptide agonists, the need for in 
vivo studies to characterise 5-opioid receptor physiology and pharmacology created demand 
for non-peptide agonists. The first reported non-peptide 5-opioid
agonist was BW373U86 ((±)-4-[(a-R*)-a-[(2S*,5R*)-4-allyl-2,5-dimethyl-l-piperazinyl]- 
3-hydroxybenzyl]-N,N-diethylbenzamide) (Fig. 1.3.). BW373U86 was shown to have 
subnanomolar activity at the 5-opioid receptor but a selectivity of only 700 fold for 5 over 
p.-opioid receptors (Chang et <3/ . ,  1993). BW373U86 was demonstrated to cross the blood 
brain barrier after subcutaneous injections resulting in a dose-related naltrindole-sensitive 
decrease in locomotor activity.
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Fig. 1.3. Comparison of the structure of the 6-opioid receptor non-peptide selective 
agonists BW373U86, SNC-80 and SNC-121.
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A methyl derivative of BW373U86, SNC 80 (Fig. 1.3.) also crosses the blood brain barrier 
and in addition has been demonstrated to have improved selectivity (>2000 fold) for the 8- 
opioid receptor compared to the parent compound (Calderon er al, 1994). Reduction of 
SNC 80 yields SNC 121 (Fig. 1.3.) which has nanomolar affinity for the 8-opioid receptor 
(Calderon et al, 1996). The SNC series of agonists has been reported to have atypical 
binding and effects at 8-opioid receptors (see Section 2.1. for further details). More 
recently a new class of 8-opioid agonists (4-diarylaminotropanes) have been synthesised 
from SNC 80, some of these analogues have been shown to have a subnanomolar potency 
and up to a 840 fold selectivity for the 8-opioid receptor over p-opioid receptor (Boyd at 
a/., 2000).
1.3.3. 8-Opioid receptor antagonists
The majority of the early opioid antagonists (e.g. naltrexone and naloxone) possessed 
affinity for all three opioid receptors, with a slightly higher affinity at the p-opioid receptor. 
The first opioid antagonist to be reported to have any selectivity for the 8-opioid receptor 
was an enkephalin analogue ICI 154,129 (N,N-diallyl-Tyr-Gly-Gly-(CH2 S)-Phe-Leu-OH), 
which was shown to have 30 fold selectivity for 8-opioid receptors (Shaw at a l, 1982). A 
series of structural analogues oflCI 154,129 were also demonstrated to possess selectivity 
for the 8-opioid receptor, however these compounds were shown to have limited potency at 
the 8-opioid receptor (Belton at a l, 1983). Improved antagonist selectivity and potency at 
the 8-opioid receptor was achieved by substitution with an a-aminoisobutyric acid moiety 
(Aib) into the ICI series of 8-opioid receptor antagonists (N,N-diallyl-Tyr-Aib-Aib-Phe- 
Leu-OH (ICI 174,864)) (Cotton e/a/., 1984). Despite the improved selectivity, these 
peptides still demonstrate some affinity for p.-opioid receptors and are metabolised by 
peptidases. This together with their agonist-like activity at high concentrations in the mouse 
vas deferens bioassay (Cohen at al , 1986) and neurotoxic effects after
intracerebroventricular or intrathecal injection in the rat (Long at al, 1988) means that ICI 
174,684 and ICI 154,129 have limited use as 8-opioid antagonists.
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Table 1.2. Summary of the selectivity of ligands at 6-opioid receptors
Structure Selectivity 
(6 vs p.)
Reference
Agonists
DADLE Tyr-D-Ala-Gly-Phe-D-Leu 6.7 Corbett et al, 1984
DSLET Tyr-D-Ser-Gly-Phe-Leu-Thr 22 Corbett e /<2 /., 1984
DPDPE Tyr-D-Pen-Gly-Phe-D-Pen 224 Erspamer e/a/., 1989
Deltorphin Tyr-D-Met-Phe-His-Leu- 3000 Erspamer e /<2 /., 1989
Met-Asp-NH]
Deltorphin I Tyr-D-Ala-Phe-Asp-Val- 21,000 Erspamer e/a/., 1989
Val-Gly-NHi
Deltorphin II T yr-D-Ala-Phe-Glu-V al- 7000 Erspamer e /<2 /., 1989
Val-Gly-NHi
RATGLU Tyr-D-Ala-(R)-Atc-Glu-Ile- 217444 Toth et al, 1997
Ile-Gly-NHz
BW373U86 See Fig. 1.3. 700 Chang et al, 1993
SNC-80 See Fig. 1.3. 2610 Calderon et a l, 1995
SNC-121 See Fig. 1.3. >1000 Ni e /<2 /., 1995
Antagonists
ICI 174,864 N,N-diallyl-Tyr-Aib-Aib- 146 Corbett e /<2 /., 1984
Phe-Leu
Naltrindole See Fig. 1.4. 123 Portoghese et a l, 1991
Naltriben See Fig. 1.4. 1446 Portoghese et a l, 1991
7-Benzylidene- See Fig. 1.4. 130 Portoghese et a l, 1992
naltrexone
Table 1.2. Values for 6-opioid receptor selectivity are taken from the reports first 
characterising the ligands.
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D-Ala^,Leu^,Cys^-enkephalin (DALCE) a synthetic enkephalin analogue was first reported 
by Bowen et al., (1986). DALCE was shown to have only moderate selectivity for 6-opioid 
receptors, but in contrast to other enkephalin analogues DALCE was shown to have a slow 
dissociation rate from 6-opioid receptors. The slow dissociation of DALCE was attributed 
to it binding covalently to a sulphydryl group of the receptor. DALCE has been shown to 
have an initial short-term agonist effect in the rat hot-plate model followed by long term 
irreversible antagonist activity (Calcagnetti eta l, 1988).
A new class of opioid peptide-derived 6-opioid antagonists were reported which contain a 
l,2,3,4-tetrahydroisoquinolone-3-carboxylic acid (Tic) residue in the 2-position of the 
peptide sequence, the two prototypic antagonists were the tetrapeptide H-Tyr-Tic-Phe-Phe- 
OH (TIPP) and the tripeptide H-Tyr-Tic-Phe-OH (TIP) (Nevin et al, 1993). TIPP showed 
high antagonist potency against various 6-opioid agonists in the mouse vas deferens 
bioassay (Ke=3-5nM), high 6-opioid affinity (Ki=1.22nM) and more than a 1000 fold 
selectivity for 6-opioid receptors. In constrast TIP was demonstrated to be less potent and 
less selective than TIPP (Nevin et a l, 1993). TIPP was shown to be unstable undergoing 
spontaneous degradation when diluted in either methanol or dimethylsulphoxide (Marsden 
et al., 1993). Structural modification of TIPP and TIP resulted in TIPP\}/ and TIPi)f, both of 
these compounds were shown to be more selective and potent at the 6-opioid receptors and 
more stable than the parent compounds (Schiller e/a/., 1993).
A breakthrough in 6-opioid research came with the report of the first non-peptide 6-opioid 
antagonist, naltrindole (Portoghese et al, 1988). Naltrindole was reported to be a 
competitive antagonist with more than a 100 fold selectivity, and an affinity of <0.0 InM 
for the 6-opioid receptor (Portoghese et al, 1988; Contreras et al, 1993). Naltrindole was 
developed using the message-address concept for the recognition of receptor by peptide 
hormones (Schwyzer et al 1977). The message sequence comprises the portion of the 
peptide that is responsible for triggering the biological effect, whilst the address portion 
represents an amino acid sequence that enables receptor binding. It had previously been
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suggested that the phenyl group of the phenylalanine residue at position 4 of the 
enkephalins is a key part of the 5-opioid receptor address (Lipowski et al 1986 ). It was 
postulated that the addition of a conformationally constrained benzene moiety to a non­
peptide opioid ligand would improve 5-opioid selectivity by mimicking the phenylalanine 
binding to a specific aromatic residue of the 5-opioid receptor address sequence.
To further this research a series of naltrindole analogues were developed with the indole 
residue of naltrindole being replaced with a variety of other heterocyclic rings in order to 
alter the conformation of the benzene ring (Portoghese et al , 1991). Naltriben, a 
benzofuran analogue of naltrindole (Fig. 1.4.) was demonstrated to be a potent and 
selective antagonist at the 5-opioid receptor. In contrast the addition of other heterocylic 
rings to the structure which forced the benzene ring into a different orientation (e.g. 
pyridine) resulted in reduced 5-opioid selectivity (Portoghese et al, 1991). The authors 
concluded from these results that the indolic benzene moiety of naltrindole was essential 
for its 5-opioid selectivity.
Further modification of the structure of naltrindole by the addition of an isothiocyanate 
group to the 5’position resulted in the production of a non-competitive antagonist (5’-NTH) 
(Portoghese et a l , 1990). Further non-competitive antagonists have been reported, these 
include the 5 -opioid selective acetylating agent N-phenyl-N-[l-(2-(4- 
isothiocyanato)phenethyl)-4-piperidinyl]propranamide HCl (FIT) (Rice, 1983) or (+)-trans- 
SUPERFIT (Rothman 1991).
7-Benzylidenenaltrexone (BNTX) has also been reported to be a non-peptide 5-opioid 
antagonist (Sofuoglu et al, 1993) which has been shown to have 130 fold selectivity for 5- 
opioid receptors compared to either p.-opioid receptors (Portoghese et al, 1992).
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OH
HO
Naltriben
7-Benzylidenenaltrexone
Fig. 1.4. Chemical structures of selective non-peptide 5-opioid receptor antagonists
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1.4. G-Protein coupled receptors
Opioid receptors belong to the superfamily of G-protein coupled receptors (GPCR). 
GPCR’s consist of a single polypeptide chain containing seven transmembrane domains 
(TMl - TM7) which loop back and forth across the lipid membrane. These domains 
exhibit helical secondary structures and pack to form a seven helices bundle. There is great 
structural homology across the cloned opioid receptor subtypes, 6-opioid receptor protein is 
66% and 58% identical to p receptor and K-receptor protein respectively, whilst p-receptor 
protein is 68% identical to K-receptor protein. The transmembrane (TM) and intracellular 
regions of the receptor proteins have the most homology (73-76% and 63-66% 
respectively). TM II and TM III exhibit the highest sequence homology, whereas TM IV 
and TM I are the least homologous of all the transmembrane regions (Zaki et al, 1996). 
The extracellular regions are the most divergent with only about 34-40% homology 
(Minami and Satoh, 1995). The striking homology between amino acid sequences of opioid 
receptor subtypes helps explain the difficulty that has been encountered in developing 
selective and stable ligands for each subtype of receptor. In addition the homology of the 
receptors across species is great. The mouse 6-opioid receptor protein has 97% amino acid 
sequence identity to the rat 6-receptor (Knapp et a l, 1995a).
The structure and function of guanine nucleotide-binding regulatory protein (G-protein) 
coupled receptors have been extensively reviewed (Bockaert, 1991; Lomize et al., 1999). 
G-proteins: are heterotrimeric proteins, consisting of an a-, P-and a y-subunit. There is 
considerable heterogeneity among G-protein subunits, particularly in the a  subunits. There 
have been reported to be as many as 18 different a-subunits (Rens-Domiano and Hamm,
1995). Under resting conditions, the a-, p- and y-subunits from a trimer, with GDP bound 
to the a-subunit. Activation of the GPCR by agonist leads to a conformational change 
resulting in decreased GDP affinity for the a-subunit of the G-protein trimer. GDP 
dissociates from the a-subunit of the G-protein trimer allowing GTP to bind and activate 
the G-protein. Activation of the G-protein is followed by dissociation of the py-subunit 
from the a-subunit. Both the a  subunit and the py complex can initiate signal transduction.
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Signal transduction is terminated by the hydrolysis of GTP to GDP by the endogenous 
GTPase of the a-subunit. The a- and py-subunits then re-associate to reform the resting G- 
protein (Bimbaumer e /û/., 1990).
G-proteins were originally characterised due to their functional responses on intracellular 
adenylyl cyclase activity. Gi-proteins inhibit whereas Gg-proteins stimulate adenylyl 
cyclase (Hamet and Claus 1988). Pertussis and cholera toxins have also been used to 
characterise G-proteins, pertussis toxin inhibits Gi, whereas cholera toxin inhibits Gg 
induced responses. There have now been a number of reports of successful G-protein 
cloning, this has allowed further characterisation of G-protein subtypes based on amino 
acid sequences.
Coupling of opioid receptors to G-proteins has been suggested for many years. The role of 
G-proteins in opioid receptor-mediated signalling has been reviewed previously (Cox, 
1993; Law, 1995). Briefly, evidence supporting opioid receptor coupling to G-proteins first 
came from the finding that the binding of opioid ligands to opioid receptors was regulated 
by guanine nucleotides and sodium (Blume, 1978a) (see Section 2.1.). Opioid drug- 
mediated inhibition of adenylyl cyclase was found to be pertussis toxin sensitive further 
supporting G-protein coupling of these receptors (Bums et al., 1983), in particular Giand 
Go. Later work utilising antisera against G-protein subunits has also demonstrated the 
involvement of G-proteins in opioid signalling (Garzon and Sanchez-Blazquez, 1994). 
More recent work has demonstrated the coupling of opioid receptors to Gg (Crain and Shen, 
1996).
The cloning of 5-opioid receptors confirmed that the receptors were G-protein coupled 
(Evans et al, 1992; Kieffer et al, 1992). The types of G-protein that are involved in Ô- 
opioid mediated responses have been extensively studied. Go and Gi- subtypes have been 
implicated in 5-opioid receptor agonist mediated antinociception. Pertussis toxin was 
shown to attenuate the antinociception of DPDPE and DELT II, whereas cholera toxin had
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no effect (Sanchez-Blaquez and Garzon, 1988). Studies utilising antisera to specific G- 
protein a-subunit have implicated Gi„2 and Gi^s in the 6 -opioid agonist mediated 
antinociception. There is some conflict regarding the involvement of Gi„i in 6-opioid 
mediated antinociception. 5-Opioid agonist mediated supraspinal antinociception has 
been shown to be unchanged in the presence of antisera for Gi^ i^ (Sanchez-Blazquez and 
Garzon, 1993), whereas spinal antinociception is reduced (Standifer et a l, 1996). These 
findings suggest that the G-protein coupling mechanisms underlying spinal and supraspinal 
antinociception may vary. Additional supports for a different mechanism for 5-opioid 
mediated spinal and supraspinal antinociception was provided by studies with antisera to 
Gg. Antisera to Gg-subtypes blocks 5-opioid agonist mediated supraspinal but not spinal 
antinociception (Sanchez-Blaquez and Garzon, 1992; Standifer e /<3 /., 1996).
Further differences in 5-opioid receptor coupling has been suggested by studies utilising 
G^ x/z antisera. Antisera to G„x/z significantly attenuated the antinociceptive effects of 
DADLE, but not of either DPDPE or DELT II. This finding suggestes that G^ x/z is capable 
of mediating 5-opioid induced antinociception with some but not all 5-opioid receptor 
agonists (Standifer et al, 1996). This leads to the intriguing possibility that different 5- 
opioid receptor ligands can activate different receptor signalling pathways, and hence may 
support the theory of agonist induced multiple receptor conformations (see Section 1.8.5.).
1.5. Function of 5-opioid receptors
1.5.1. Phvsiologv and pharmacologv
With the discovery of drugs with increased selectivity for the 5-opioid receptor came 
increasing knowledge of the function of the 5-opioid receptor. Initially supraspinal 
antinociception was thought to be mediated solely through p.-opioid receptor activation as 
drugs that potently inhibited the isolated guinea-pig ileum but not those which potently 
inhibited the field stimulated mouse vas deferens were shown to produce antinociception. 
However with the development of selective 5-opioid receptor agonists and antagonists 5- 
opioid agonists were also shown to mediate antinociception. Supraspinal 5-opioid
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receptors were proposed to mediate antinociception based on the finding that whilst 
intracerebroventricular (i.c.v.) injection of either p-opioid agonists (such as DAMGO and 
morphine) or 6-opioid agonists (e.g. DPDPE) produced antinociception, only p-opioid 
agonists altered gastrointestinal (GI) transit (Galligan et al, 1984; Porreca et al, 1984). 
Further evidence for the involvement of 6-opioid receptors in supraspinal antinociception 
was provided by studies utilising the 6-opioid receptor antagonist ICI 174,864. ICI 
174,864 has been shown to effectively antagonise i.c.v DPDPE mediated antinociception 
but not the antinociception induced by i.c.v. DAMGO or morphine in the mouse tail flick 
model. Conversely, the p-opioid receptor antagonist p-funaltrexamine (PPNA) has been 
shown to antagonise DAMGO and morphine, but not DPDPE mediated antinociception 
(Heyman et al., 1987). Mice which are deficient in p-opioid receptors (e.g. CXBK mice) 
have been utilised to demonstrate the involvement of 6-opioid receptors in antinociception. 
CXBK mice have been reported to have reduced antinociception to DAMGO and morphine 
whilst retaining 6-opioid agonist mediated antinociception (Mathiasen et al, 1987; Vaught 
et al, 1988).
6-Opioid receptors have also been demonstrated to mediate spinal antinociception. 
Intrathecal (i.t.) administration of DPDPE produces antinociception which is reversible by 
ICI 174,864 in both the rat and mouse (Rodriguez et al, 1986; Heyman et a l, 1987). In 
contrast to this finding i.t. DAMGO mediated antinociception is not inhibited by ICI 
174,864. Similarly the administration of the p-opioid receptor antagonist ppNA inhibited 
DAMGO but not DPDPE induced antinociception (Heyman et al, 1987). A synergistic 
interaction between spinal and supraspinal opioid mediated antinociception has been 
proposed for several years (Rossi et al, 1993, 1994). Activation of supraspinal opioid 
receptors has been proposed to activate inhibitory descending pathways resulting in the 
release of neurotransmitters at the spinal level. Spinally administered opioid agonists have 
been proposed to interact with these transmitters resulting in enhanced antinociception 
(Yeung and Rudy, 1980). Recently a spinal and supraspinal antinociception synergy for 6- 
opioid agonists including DPDPE and deltorphin I has been reported (Kovelowski et al,
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1999). For a review on 5-opioid receptor mediated antinociception the reader is directed to 
Heyman et al (1988), Porreca and Fields (1993) and Yaksh (1993).
Endogenous opioids have been implicated in the regulation of the cardiovascular system 
(for a review see Faden 1993) Opioid peptides and receptors are found in the regions of 
the central nervous system that are involved in cardiovascular regulation, such as the 
hypothalamus, nucleus ambiguus, nucleus tractus solitarius and intermediolateral nucleus 
(Khachaturian et al, 1985). Studies utilising selective opioid receptor antagonists have 
demonstrated that in general endogenous peptides have little effect on cardiovascular 
function in normal, non-anaesthetised or unstressed animals. These findings suggest that 
the endogenous opioid system is not tonically active in regulating the cardiovascular 
system (Holaday, 1983). However endogenous opioids have been implicated in certain 
pathophysiological conditions including shock and hypertension. The non-peptide 5- 
opioid antagonist (ICI 154,129) has been demonstrated to reverse hypotension in endotoxin 
shock, whilst having no effect on morphine mediated antinociception (Holaday et al,
1982). Opioids are known to mediate hypotensive effects (Holaday and Ward, 1982; Giles 
et al, 1983; Holaday, 1983; Pfeiffer et al, 1984; Pfeiffer and Illes, 1984; Levin et al, 
1986; Szabo and Hedler, 1986), the administration of opioid antagonists cause a reduction 
in blood pressure in rats which are spontaneously hypertensive (Quock et a l, 1985). Other 
pathophysiological conditions have also been implicated to involve opioid receptors. 
Activation of opioid receptors has been implicated in the development of ischaemic 
preconditioning. 5-Opioid receptors have been shown to be involved in the signalling 
pathway of ischaemic pre-conditioning and the reduction of infarct size in rat hearts 
(Schultz et al, 1995). This preconditioning has been demonstrated to be mediated through 
a peripheral mechanism (Schultz et al, 1997).
Opioid receptors are also important in the regulation of the gastrointestinal (GI) tract 
Opioid agonists have been used as antidiarrhoeal agent for many years. Opioid receptors 
are widely distributed throughout the GI tract but the expression of the different opioid
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receptor subtypes has been demonstrated to be species dependent (Nishimura et a l, 1986; 
Smith et al, 1988; Fickel et al, 1997). Opioid agonists have two main actions on the GI 
tract, antimotility and antisecretory (for review see Kromer, 1993) 5-Opioid-agonists have 
been shown to inhibit secretion of fluid and electrolytes and to reduce gastrointestinal 
motility (Manara and Bianchetti, 1985; Tavani et al, 1990; Pol et al., 1994; Broccardo et 
al, 1998). Acute intestinal inflammation has been reported to sensitise 5-opioid receptors, 
resulting in increased DPDPE mediated anti-secretory and anti-transit activity in mice (Pol 
et a l, 1994). The effects of 5-opioid agonists on gastrointestinal function has been shown 
to be mediated by receptors at spinal, supraspinal and peripheral tissues (Manara and 
Bianchetti, 1985; Burks et al, 1987). In contrast to the guinea-pig, the isolated field 
stimulated mouse ileum has been shown to be potently inhibited by 5-opioid receptor 
agonists (Smith er a/., 1988). Peripheral administration of DADLE in guinea-pig ileum 
results in an antisecretory action which is antagonised by ICI 174,864 (Vinayek er al,
1983). In contrast to this finding i.t and i.c.v., but not peripheral administration of 5-opioid 
agonists have been shown to reduce GI tract secretions in mice (Jiang et a l ,  1990). The 
actions of 5-opioid agonists in the GI tract is clearly species dependent, which would be as 
expected due to the species difference in the expression of the receptors.
5-Opioid agonists have been implicated in the treatment of Parkinson’s disease (Hudzik et 
al, 2000), however little evidence is currently available to support this possibility. Studies 
utilising rats with a unilateral 6-hydroxydopmaine legion have demonstrated that 5-opioid 
receptor agonists augment dopaminergic function on the unlesioned side of these animals. 
Furthermore the effect of L-3,4 dihydroxyphenylalanine (L-DOPA) was potentiated by 5- 
opioid receptors agonists on reserpine-induced suppression of motor activity (Hudzik et 
al, 2000). From these findings the authors propose that 5-opioid agonists may potentiate 
the dopaminergic system by inhibiting cholinergic activity in the striatum, and thus be a 
viable treatment in Parkinsons disease.
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Opioids have also been implicated in the modulation of immune responses. There have 
been a number of reports of immunosuppresive and immunoenhancing effects of opioids in 
both in vivo and in vitro models. Pharmacological doses of morphine have been shown to 
result in immunosuppressive responses in several mammalian species, including man (for a 
review see Byrant and Holaday, 1993). Both physiological and pathological situations 
involving the endogenous opioid system have been suggested to lead to insufficient 
immune defence against infections or cancer. Such situations could include stress, long­
term opioid treatment of chronic pain and drug addiction (Byrant and Holaday, 1993). 6- 
Opioid receptor transcripts in immune cells have been reported (Gaveriaux et al, 1995), as 
have 5-opioid receptors associated with lung cancer cells (Roth and Barchas, 1986; 
Manackjee and Minna, 1991). In contrast to the immunosuppressive effect of p.-opioid 
receptors agonists, 5-opioid receptor agonists have been shown to substantially reduce the 
propagation of the Human Immunodeficiency Virus-I in T-cells (Sharp et al, 1998).
1.5.2. Second messenger svstems
5-Opioid receptors have been demonstrated to inhibit cAMP in a number of systems. The 
cAMP decrease has been shown to be at least partly mediated through increased 
phosphodiesterase activity (Law and Loh, 1993). This increase in phosphodiesterase 
activity has been shown to be pertussis toxin insensitive, suggesting that this effect is not 
mediated through either Gi or Go subtypes. 5-Opioid receptors have also been reported to 
mediate agonist stimulation of mitogen-activated protein kinase (MAP kinase) (Fukuda e/ 
al, 1996). The MAP kinase family has been shown to cause phosphorylation of the 5- 
opioid receptor. This effect was shown to be mediated through Gi and Go-subtypes as there 
was no elevation of MAP kinase in the presence of pertussis toxin. Furthermore this effect 
was demonstrated to be mediated through the py-subunit (Belcheva e? al, 1998). There are 
now several reports of stimulatory effects of opioids, including stimulation of cAMP 
formation, phospholipase C activation and increases in intracellular calcium ion 
concentration (Crain and Shen, 1996). The reader is directed to a review by Quock (1999) 
for a more thorough discussion of signal transduction after 5-opioid receptor activation.
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6-Opioid receptors have been shown to regulate intracellular calcium concentrations. The 
5-opioid selective agonist DADLE has been shown to inhibit cellular calcium currents in a 
pertussis toxin sensitive manner (Hescheler et al, 1987). Cloned and expressed 5-opioid 
receptors have been shown to couple to both L type and N type Ca^  ^channels through Gi 
proteins (North, 1993; Sher et a l, 1996). 5-Opioid receptors have also been reported to 
increase intracellular calcium concentration by releasing calcium from intracellular stores 
(Allouche et a l, 1996). 5-Opioid receptors have also been implicated in the control of 
channels. Increased potassium conductance has been demonstrated after 5-opioid receptor 
activation in guinea-pig neurons (Mihara and North, 1986). For ftirther discussion of ion 
channels and 5-opioid receptors the reader is directed to a review by North (1993).
1.6. 5-Opioid recognition sites
The mechanism by which agonists and antagonists recognise and activate 5-opioid 
receptors has been the focus of much work. The ligand binding domain of G-protein 
coupled receptors is generally believed to be composed of several charged residues with a 
hydrophobic pocket created by transmembrane spanning regions. A conserved aspartate in 
the second transmembrane spanning regions of the az-adrenergic receptor has been 
reported to be critical for agonist binding (Horstman et al, 1991). The cloned 5-opioid 
receptor (Evans et al, 1992; Kieffer et a l, 1992) also has an aspartate within the second 
transmembrane (TM) spanning region (residue 95). It has been reported that this aspartate 
is important for high affinity 5-opioid selective agonist binding (DPDPE and DSLET) but 
not non-specific agonist (bremazocine and buprenorphine) or antagonist (naltrindole and 
BNTX) binding (Kong et a l, 1993). Additionally this aspartate residue of 5-opioid and 
a 2-adrenergic receptors has been suggested to be responsible for Na^ regulation of agonist 
binding (Horstman et al, 1990; Kong et al, 1993) (see Section 2.1.).
Chimeric receptors have been utilised to elucidate regions of the 5-opioid receptor that are 
important for selective 5-opioid ligand binding (Fukuda et al, 1994; Li et a l, 1996).
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Fukuda et al. (1995) reported that high-affinity binding of Ô-selective peptide ligands is 
mediated through distinct domains compared to those which are responsible for p.-opioid 
selective ligand binding. The extracellular amino terminus (N-terminus) of p.-and 
5-opioid receptors differ considerably in their amino acid sequence, despite this the N- 
terminus has not been demonstrated to be involved in opioid ligand selectivity. Instead the 
TM spanning regions V-VII of the 5-opioid receptor has been determined to afford high 
affinity and selective binding of 5-opioid agonist (DPDPE) (Fukuda et al, 1995). The third 
extracellular loop of the human 5-opioid receptor has also been reported to be involved 
with both naltrindole (Li et al, 1996) and agonist selectivity (Varga gf al, 1996). The third 
extracellular loop of the 5-opioid receptor has been demonstrated to be important for 
binding of both peptide (DPDPE and DELT II) and non-peptide agonists (SNC 80 and 
TAN 67) (Varga et al, 1996). However, it has been suggested that the different classes of 
5-opioid agonists interact with different residues of the third intracellular loop. A recent 
study has confirmed this suggestion, demonstrating that recognition of the peptide ligands 
(e.g. pCI-DPDPE and deltorphin II) differs from the recognition of the non-peptide ligand 
SNC 121 (Li et al, 1995). Mutagenesis studies of human 5-opioid receptors demonstrated 
that a tryptophan residue (284) in the third extracellular loop was essential for SNC 121 
binding but not for either of the peptide ligands. This finding provided strong evidence for 
alternative sites of recognition of peptide and non-peptide ligands. A recent report (Filizola 
et al, 1999) has utilised computer-aided design to construct 3D models of opioid receptors 
to allow the identification of key residues involved in direct interaction with the ligand. 
The findings from this study agreed with the findings from the mutagenesis studies, 
confirming the viability of this approach in topography studies.
Studies to identify the residues of the 5-opioid receptor important in receptor function have 
also been reported. The intracellular carboxy terminus (C-terminus) of the 5-opioid 
receptor has been shown not to be required for agonist selectivity, transportation and 
localisation of the receptor to the membrane or agonist-dependent activation of the receptor 
(Zhu et al, 1997), However the C-terminus of the 5-opioid receptor is not redundant. In
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common with other receptors (for a review see Dohlman, 1991) the C-terminus of the 5- 
opioid receptor has been demonstrated to be involved with receptor internalisation and 
desensitisation (Cvejic et al, 1996; Trapaidze et al, 1996). In addition serine and 
threonine residues of the C-terminus of the 5-opioid receptor have been suggested to be 
phosphorylation sites for kinases such as protein kinase C. 5-Opioid receptors with a 15 
amino acid truncation in the C-terminal tail were shown to behave similarly to wildtype 
receptors in response to chronic agonist treatment. In contrast to this, deletion of the 
terminal 37 amino acids in the C-terminus resulted in attenuation of the down-regulation of 
5-opioid receptors after chronic DADLE treatment (2-48hour) (Cvejic et a l, 1996). A 
single residue of the cytoplasmic tail of the murine 5-opioid receptor was implicated in 
agonist induced down-regulation after a mutation of a single residue of the cytoplasmic tail 
(threonine^^  ^ to alanine^^^) resulted in attenuation of down-regulation. In contrast to the 
murine 5-opioid receptor the human 5-opioid receptor has an alanine at position 353 
(Knapp et al, 1994). From this finding it has been proposed that agonist induced down- 
regulation of the human 5-opioid receptor is mediated through a different mechanism than 
the murine 5-opioid receptor.
The regions of the 5-opioid receptor responsible for mediating interactions with G-proteins 
have also been studied. Peptides which are site specific for certain regions of the 5-opioid 
receptor have been utilised to assess which regions influence agonist activation and G- 
protein dependent high affinity binding (Merkouris et al, 1996). The peptides were made 
homologous to various regions of the 5-opioid receptor, including the C-terminus tail and 
the third and second intracellular loop. The involvement of the third intracellular loop of 
the 5-opioid receptor in G-protein activation was suggested after GTPase activity and 
[^^SjGTPyS binding was shown to be reduced in the presence of the peptide homologous 
to the third intracellular loop. In contrast to this finding the presence of the peptide 
homologous to the second intracellular loop did not significantly affect either GTPase 
activity or [^^SJGTPyS binding. However, the peptide homologous to the C-terminal tail of 
the 5-opioid receptor was shown to slightly increase [^^SjGTPyS binding, suggesting that
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the C-terminal tail of the receptor did influence G-protein activation (Merkouris et al,
1996). These results were largely supported by the findings from experiments investigating 
the effects of the peptides on [^HJDSLET binding. Receptor-G-protein interactions are 
known to modulate the affinity of agonist binding to receptor. The peptide homologous to 
the third, but not the second, intracellular loop, decreased [^H]DSLET binding, suggesting 
that the third intracellular loop is involved with G-protein coupling. A difference between 
the two assays was apparent with the findings that the peptide homologous to residue 322 
to 333 of the cytoplasmic tail of the 5-opioid receptor, did not involve G-protein activation 
whilst it did decrease [^HJDSLET binding (Merkouris et al, 1996). In contrast to this 
study, the C-terminal tail has been implicated in the coupling of 5-opioid receptor to 
phospholipase C (Hirst et a l, 1998).
Studies utilising chimeric receptors have also indicated that regions of the 5-opioid 
receptor, which are not thought to be in close proximity to G-proteins, can also modulate 
receptor-mediated signal transduction. A }i-/5-opioid receptor chimera has been reported in 
which the N-terminus through to the first extracellular loop of the 5-opioid receptor was 
replaced with the |i-opioid receptor (Claude et a l, 1996). This mutation was shown not to 
influence DPDPE-induced inhibition of forskolin-stimulated cAMP production in 
transfected CHO cells. However, a number of 5-opioid antagonists (including naloxone, 
naltrexone, naltrindole and naltriben) also behaved as agonists at the chimeric receptors. A 
point mutation of the chimeric receptor was found that resulted in a mutation of the fourth 
TM domain. This mutation resulted in a serine residue in TM IV being a leucine residue. 
On back mutation of the leucine to a serine, the 5-opioid selective antagonists did not 
behave as agonists (Claude et al, 1996). From these findings it has been suggested that 
ligand interaction with residues of TM IV can alter the conformation of the 5-opioid 
receptor to permit receptor coupling to second messenger systems (Quock et al., 1999).
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1.7. 5-Qpioid receptor desensitisation
Receptor desensitisation on prolonged exposure to agonists is a phenomenon common to 
many G-protein coupled receptors. Chronic exposure to opioid receptor agonists results in 
the development of both tolerance and dependence. Over the years a number of theories 
have been proposed to explain the development of tolerance and dependence and it seems 
clear that there is not one underlying mechanism that is responsible for both phenomena. 
Tolerance has been suggested to develop through four separate mechanisms, desensitisation 
of the receptor, compensatory changes in intracellular signalling, compensatory changes in 
neuronal circuitry and learning (Beaumont and Henderson, 1999). This thesis concentrates 
on effects at the receptor level and for this purpose a brief overview of receptor 
desensitisation will be provided.
Receptor desensitisation has been suggested to be mediated through different mechanisms 
including receptor phosphorylation, uncoupling of the receptor from G-proteins and 
reduction of the expression of receptors on the cell membrane (through internalisation of 
the receptor) (Hasbi et al, 2000).
Chronic DADLE treatment has been suggested to uncouple 5-opioid receptors from G- 
proteins in rat brains (Tao et al, 1993). Agonist induced uncoupling of 5-opioid receptors 
has been suggested to prevent the development of tolerance. In agreement with this 
suggestion methadone, a non-selective opioid agonist which does not cause as much 
tolerance as morphine, has been demonstrated to induce uncoupling of the 5-opioid 
receptor whereas morphine does not (Liu et al, 1999).
After agonist activation and uncoupling of the receptor, the 5-opioid receptor is 
phosphorylated. This phosphorylation is initiated by the Py subunit of G-proteins which 
facilitates the translocation of G-protein kinases (GRK’s) to the plasma membrane. In 
particular GRK 2 has been implicated in phosphorylation of 5-opioid receptors (Pei et a l,
1995). A serine or threonine residue of the C-terminus tail of the 5-opioid receptor is
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phosphorylated and this leads to increased affinity of P-arrestin for the receptor (Trapaidze 
et al, 1996). Phosphorylation of the 5-opioid receptor has been reported to precede 
receptor internalisation. Clarithin coated pits are recruited by the arrestin-5-opioid receptor 
complex and the receptors are internalised (Trapaidze et al, 1996). For a review of the 
effect of receptor kinases and arrestins on GPCR’s the reader is directed to Krupnik and 
Benovic (1998).
5-Opioid receptors phosphorylation has been suggested to involve other kinases which do 
not enhance arrestin binding, including protein kinase A, protein kinase C and mitogen 
activated kinases (see Beaumont and Henderson, 1999). The 5-opioid receptor needs to be 
converted from the dimer to the monomer form of the receptor before internalisation of the 
receptor (Cvejic and Devi, 1997). Morphine has been demonstrated not to cause either the 
internalisation of the 5-opioid receptor or the conversion of the dimeric receptor to the 
monomer (Keith et al, 1996; Whistler et a l, 1999) (see Section 1.8.).
It is clear that morphine does not behave typically in several of the mechanisms that have 
been reported to be responsible for receptor desensitisation, from conversion of the dimer 
to the monomer, uncoupling of the receptor from G-protein and internalisation of the 
receptor. It has been suggested that these findings may explain why morphine induces 
tolerance and dependence whereas the endogenous opioids do not (Whistler et a l, 1999).
1.8. G-protein coupled receptors -  Monomers, dimers or oligomers ?
Classically G-proteins were thought to exist and function as monomers. As early as 1982 
there was evidence from crosslinking studies that G-protein coupled receptors may exist as 
dimers. Studies with several GPCR’s show that the co-expression of two mutant receptors, 
which individually do not bind or transduce signals, results in receptors that bind and 
transduce signals (Kobilka et al, 1988; Maggio et al, 1992). These data implied that a 
functional complementation is achieved by intermolecular interaction between receptor 
molecules. Cross-linking and immunoprécipitation studies have shown that p2-adrenergic
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receptor can form homodimers. This homodimerisation can be inhibited by a peptide that 
is derived from transmembrane VI of the receptor (Herbert et al, 1996).
Pharmacological data has suggested the existence of opioid receptor dimers for several 
years. An interaction between p.- and Ô-opioid receptors was proposed to explain the 
effects of 5-opioid agonists in |i-opioid receptor mediated analgesia (Rothman and 
Westfall, 1982; Rothman et ah, 1993) (see Section 1.10.). The first direct evidence of 
opioid receptors existing as dimers was provided by Cvejic and Devi (1997). They 
reported homodimerisation of 5-opioid receptors from their studies utilising cross-linking 
and immunoprécipitation of tagged (either c-Myc or Flag) 5-opioid receptors. The level of 
dimérisation of the 5-opioid receptors was shown to be agonist dependent, an increase in 5- 
opioid agonist concentration resulting in a decrease in the level of dimers and a 
corresponding increase in the levels of receptor monomers. Pre-incubation of the cells with 
naloxone prevented the agonist-induced decrease in dimers. The C-terminal tail was shown 
to be important in the formation of dimers as a mutant 5-opioid receptor with a 15 residue 
deletion in the C-terminal tail has been shown not to form dimers (Cvejic and Devi, 1997). 
Both DAMGO and morphine have been shown not to influence the level of 5-opioid 
receptor dimérisation. The time course of the agonist-induced inter-conversion between the 
dimer and monomer was shown to be quicker than the reported agonist-induced 
internalisation of the 5-opioid receptor. Together with the previously reported finding that 
morphine does not cause internalisation of the 5-opioid receptors (Keith et a l, 1996) these 
findings lead Cvejic and Devi (1997) to postulate that the inter-conversion of the dimer to 
the monomer was a necessary preceding step before agonist-induced internalisation of the 
receptor.
A later study demonstrated the existence of k - and 5-opioid receptor heterodimers (Jordan 
and Devi, 1999). This study reported not only the existence of heterodimers, but also that 
dimers compared to the monomers, exhibit different binding profiles of both 5 and k  opioid 
receptor agonists and antagonists. Both 5 -  and K-agonists (DPDPE and U69593) were
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shown to have reduced affinity for the dimer as compared to their respective monomers (5 
for DPDPE and k  for U69593). However, the presence of both agonists resulted in 
synergistic binding at the K-Ô heterodimer. This synergistic binding was also shown to 
lead to increased effector fimction. The presence of both agonists resulted in decreased 
intracellular cAMP concentration of the cells expressing the heterodimer as compared to 
the presence of either one or the other of the agonists alone (Jordan and Devi, 1999). These 
findings give further support to the hypothesis that a physically interacting association 
between p.- and 5-opioid receptors may result in the pharmacological data that has been 
reported (see Section 1.9.).
Recent reports have suggested that GPCR’s not only exist and maybe function as dimers 
but also oligomers. Oligomers have been suggested after recurrent observations in western 
blot analysis of immunoreactive bands that might correspond to complexes of three, four or 
more receptors. There is evidence from experiments utilising fluorescence resonance 
energy transfer that the a  factor receptor (a GPCR from yeast) exists as an oligomer in both 
intact cells and membranes (Overton and Blumer, 2000). The authors propose that 
oligomerisation of the receptors may facilitate signalling.
Although there is evidence that many GPCR’s exist as dimers or oligomers, including 
opioid-, dopamine, ^-adrenoceptors and GAB A receptors (Maggio et al, 1992; Cvejic et 
al, 1996; Herbert et al, 1996; Jordan and Devi, 1999), the overall regulation of these 
structures by agonists is not universal. Reports have been published that demonstrate 
agonists increase dimérisation of some receptors such as ^-adrenoceptors (Herbert et al,
1996), whilst agonists can inhibit dimérisation of other receptors including opioid receptors 
(e.g. Cvejic and Devi, 1997) or they may influence the level of receptor dimérisation (e.g. 
the a  factor receptor (Overton and Blumer, 2000)). What is clear is that dimérisation of 
GPCR’s leads to pharmacological effects that are distinct from the pharmacology of the 
monomer, it is possible that dimérisation will be responsible for receptor subtypes that have 
been proposed from pharmacological data but which cannot be identified with molecular
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biology. From their different pharmacological profile dimers have been suggested be a 
target for drug development (Jordan and Devi 1999). Furthermore dimers and oligomers 
have been suggested to be associated with human disease (Overton and Blumer 2000). For 
example it has been suggested that schizophrenics may have reduced levels of D2 
dopamine receptor dimers compared to control patients (Overton and Blumer, 2000).
1.9. Receptor Models
Traditional receptor theory has postulated a single resting receptor state to which agonists 
bind inducing a conformational change of the receptor to an activated (functional) state. 
Antagonists were believed to bind to the receptor without inducing a conformational 
change, but prevent agonist binding and thus activation of the receptor(Del Castillo and 
Katz, 1957). The interactions between agonist, receptor and G-proteins is relatively 
undisputed (see Section 1.5.), however the stoichiometry and nature of the proteins during 
activation remains unclear. The concept of agonist-induced receptor conformations has 
been the subject of much debate. In order to prevent constant activation the existence of an 
inactive receptor conformation is assumed. The inactive receptor state is proposed to adopt 
a conformation which shields the peptide sequences of the receptor responsible for 
interacting with the G-protein. Upon agonist binding the receptor molecule must undergo a 
conformational change revealing the active G-protein site. Several models have been 
proposed to explain pharmacological data that suggest different receptor conformations are 
induced after ligand binding.
1.9.1. Temarv Complex Model
The ternary complex model was first described to explain agonist binding to the 13- 
adrenoceptor (De Lean et al, 1980). De Lean et al, (1980) postulated the active form of 
the receptor involved a ternary complex between the hormone (agonist), receptor and an 
additional membrane component (which is now known to be G-protein) (Fig. 1.5.). The 
existence of the ternary complex was supported by evidence that suggested a larger 
molecular size of the agonist-receptor complex than the antagonist-receptor complex
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(Limbird and Lefkowitz, 1978). In the ternary complex model agonists are proposed to 
stabilise the receptor-G-protein (RG) complex by binding to specific residues of the 
receptor and inducing a conformational change in the receptor, including the intracellular 
loop. In contrast to agonists, it was postulated that antagonists did not promote the 
formation of the ternary complex and thus were without biological effect. The ternary 
complex provides an explanation for different efficacies of agonists. An equilibrium 
constant, L, reflects the ability of the agonist to promote the formation and stabilise the 
ternary complex, whereas K reflects the affinity of an agonist for the receptor (see Fig.
1.5.).
1.9.2. Extended temarv complex model
The ternary complex model was adapted following the construction of a mutated p2- 
adrenergic receptor. When expressed in CHO cells the mutant receptor showed constitutive 
activity (agonist-independent activation of adenyl cyclase), increased affinity for agonists 
but not antagonists and increased agonist efficacy. The ternary complex model could not 
adequately explain these findings and the extended ternary complex model (ETCM) was 
developed (Samama et al, 1993). In contrast to the ternary complex model the extended 
ternary complex model has two receptor states, an active R* and an inactive R 
conformation (Fig. 1.6.). An equilibrium between the two receptor conformations is 
assumed. The ETCM proposed that only the R* form of the receptor can bind to G-protein 
and therefore is the only receptor state that can form a ternary complex (agonist, receptor 
and G-protein). In this model the capability of the ligand to induce the formation of the 
ternary complex depends on two factors. Firstly, its ability to facilitate the transition of the 
receptor from the resting R state to the active R* conformation and secondly, the ligands 
ability to stabilise the ternary complex (see Fig. 1.6.).
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Fig 1.5. Schematic representation of the ternary complex model.
A+R+G
AR+G
(Low affinity)
(Pre-coupled)
A+RG
ARG
Fig. 1.5. The model involves the interaction of the agonist (A), the receptor (R) and a 
membrane component (G). ARG represents the active ternary complex. M represents the 
affinity of G-protein for free receptor, L represents the affinity of G-protein for the ligand- 
receptor complex, whilst K and K’ represent the affinity of the ligand for the uncoupled and 
coupled receptor state respectively (De Lean et al, 1980).
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Furthermore in the ETCM GTP analogues are proposed to act by preventing the formation 
of R*G, in contrast to the ternary complex model this results in two receptor states still 
being apparent in the presence of GTP analogues (see Section 2.1.).
1.9.3. Leff two and three state model
An alternative model to the extended ternary complex model, the two state model has been 
proposed by Leff (1995). Similar to the ETCM the two state model also assumes that the 
receptor exists in two conformations with an equilibrium between the active (R*) and 
inactive (R) state (Fig. 1.7.). It is worth noting that in the two state model the active (R*) 
state of the receptor incorporates the G-protein and is therefore different to the R* receptor 
state of the extended ternary complex model. In the two state model, in the absence of 
agonist the distribution of the two receptors states is dependent on both the receptor and 
system. Agonists are assumed to have higher affinity for the R* receptor conformation. 
On binding to R* a complex is formed between agonist and receptor (AR*) which 
effectively depletes R*. This depletion of R* forces the equilibrium away from R towards 
R* and results in a biological effect. In contrast antagonists are assumed to have equal 
affinity for R and R*, consequently not altering the equilibrium and thus having no effect.
A further model has been proposed by Leff, the three state receptor model (1997). This 
model has been used to explain pharmacological data in which a single receptor activates 
two effector pathways. The three state model proposes three receptor states, the uncoupled 
receptor (R), receptor coupled to one effector pathway (R*) and receptor coupled to a 
different receptor pathway (R**). Agonists are proposed to have different affinities for the 
two active receptor states (R* and R**) and stabilise them to different extents.
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Fig 1.6. Schematic representation of the extended ternary complex model.
A + R + G  ±
A
A  + R* +  G 1
M
A
\ /
A  +  R*G
K
PK
aPK
■» AR + G
A
PJ
AR* + G
A
\ /
aM
AR*G
Fig. 1.6. The model involves the interaction of the agonist (A), G-protein (G) and the 
active and inactive receptor (R* and R) conformation. AR*G represents the active ternary 
complex. K represents the affinity of the ligand for the receptor, ! is the equilibrium 
between R and R* and M represents the affinity of G-protein for R*. Two further constants 
are incorporated into the model, a  which describes the agonists ability to stabilise the 
ternary complex and P which describes the extent ligand binding influences the equilibrium 
between R and R* (Samama et ol, 1993).
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The extended ternary complex, the cubic ternary complex and the two state model all 
describe the receptor as either being active (R*) or inactive (R). It has been suggested that 
this is an over-simplification of a much more complex scenario. Multiple agonist-induced 
receptor conformations have been proposed, where the conformation change induced by 
one ligand is specific for that ligand (Krumins and Barber, 1997; Tucek, 1997; Strange, 
1998; Kenakin, 1999). These specific receptor conformations may signal differently to G- 
proteins and this could potentially explain the phenomenon of a single receptor activating 
different effector pathways. To add to this already complex field, there is some data that 
suggests that some ligands may induce conformations that do not reveal their presence by a 
physiological response but in other ways. For example the cholecystokinin (CCK) receptor 
antagonist D-Tyr-Gly[(Nle28,32,DTrp30)-cholecystokinin-26-32] phenylethylester, does 
not produce an acute physiologcal response but does accelerate CCK receptor 
internalisation (Roettger, 1997). This finding suggests that the ligand induces a receptor 
conformation that directs the receptor into an endocytotic pathway whilst not initiating a 
measurable physiological response.
1.9.5. Interacting receptor model
Recently a receptor model termed the interacting receptor model (IRM) has been proposed 
based on the two state model (Onarun and Gurdel, 1999) (Fig. 1.8.). The IRM was 
proposed to incorporate the phenomenon of receptor dimérisation and the reported 
functional change that occurs in such systems (Cvejic and Devi, 1997; Jordan and Devi, 
1999). In the IRM active receptor monomers (R*) interact with each other to form dimers 
which contributes to the stabilisation of the active receptor state. This stabilisation of the 
active receptor state results is proposed to induce no change in antagonist affinity, whilst 
increasing apparent agonist affinity and decreasing inverse agonist apparent affinity. 
Increasing the receptor expression has a similar effect on the affinity of agonist, antagonists 
and inverse agonists.
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Fig 1.7. Schematic representation of the two state model.
A
+
R
A
A R l
(Resting)
L
A
+
R*
A
\/
AR*
(Active)
The receptor exists in two states, resting (R) and active (R*). The distribution of the two 
states is governed by the equilibrium constant L. The agonist has affinities for the two 
states as determined by constants KAand Ka* (Leff, 1995).
Fig 1.8. Schematic representation of the interacting receptor model.
R* + R*
L
± R*R*
2PK PK/2
A + R*R* < > A + AR*R* < > AR*AR*
Fig. 1.8. A represents agonist, R* and R* two receptors of a single type in the active 
conformation and R*R* represents a homodimer of the active receptor state. Ligands are 
assumed to have different affinities for the various conformations (Onaran and Gurdel, 
1999).
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The IRM was supported by the results from studies utilising mice that over-expressed the 
P2-adrenergic receptor (Onarun and Gurdel, 1999).
1.9.6. Cubic Temarv Complex Model
The cubic ternary complex (CTC) model (Weiss et al, 1996a, b) is based upon the 
extended ternary complex (Samama et al, 1993) (see Section 1.9.2.). It incorporates all the 
features of the extended ternary complex model, with the addition of allowing an 
interaction between G-protein and inactive receptor (i.e. R). In the CTC model, eight 
receptor species are assumed to exist at equilibrium with the ligand, four native receptor 
species and their four ligand-bound counterparts (Fig. 1.9.).
The CTC model was developed as a mathematical exercise to explore the pharmacological 
implications of allowing G-protein and inactive receptor interactions. The CTC model is 
reported to be complete both thermodynamically and statistically. The authors (Weiss et 
al, 1996a, b) report that the CTC model provides a framework by which other 
pharmacological models can be evaluated. However in the absence of any pharmacological 
data supporting such a complex model, this model, as yet, is not required to explain 
receptor, ligand and G-protein interactions.
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Fig 1.9. Schematic representation of the cubic ternary complex model.
ARiG ^  8ap K a
AR
AR.G
5ayK/
Fig. 1.9. Receptors are assumed to exist in an inactive (Ri) and active (Ra) conformations, 
which may or may not be coupled to G-proteins. Receptors are either ligand bound (top 
layer) or ligand free (bottom layer). In the absence of ligand the receptor exist in 
equilibrium between four receptor species, which are Ri, Ra, RiG and RaG. The equilibrium 
constants that exist between the four species are described as Kq, Kact, PKq and pKact- Each 
of these receptors can bind to ligand and the equiilbrium describing these responses 
described as Ka, œKa, yKa and ôayKA. The interconversions of the ligand bound receptors 
are described as aKaci, yKg, byPKo and ôaPKact- (Weiss et al, 1996a, b).
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1.10. 5-Opioid receptor subtypes
1 .10 .1 . SçQtnplexed Slid Snnn-rnmpleypH Opioid reCeptOF SUt)typ0S
Both in vivo and in vitro evidence has been reported to support the existence of 5-opioid 
receptor subtypes. The existence of a functional complex between 5 -  and p.-opioid 
receptors has been postulated for several years (Lee e/ al, 1980; Rothman and Westfall, 
1982; Vaught et al, 1982). The opioid receptor complex is thought to be composed of 
distinct but physically interacting p. and 5-opioid receptors. The first evidence to support a 
p-/5-opioid receptor complex was provided from findings that demonstrated that sub- 
effective doses of 5-opioid receptor agonists modulate morphine-induced antinociception 
(Vaught and Takemori, 1979). Sub-effective doses of Leu^-enkephalin potentiate (Vaught 
and Takemori, 1979) whilst Met^-enkephalin attenuate morphine induced antinociception 
(Lee and Leybin, 1980). From this data it was suggested that morphine mediates its 
antinociceptive activity at least partly through the p-opioid receptor site of the p/5 -receptor 
complex. Sub-effective doses of 5-opioid receptor ligands that have greater selectivity than 
the enkephalins have also been demonstrated to modulate morphine antinociception. Sub- 
effective doses of DADLE, DSLET and DPDPE potentiate morphine induced 
antinociception (Barrett and Vaught, 1982; Heyman et al, 1989a) , whereas [D- 
Ala^,Met^] enkephalinamide (DAMA) has been shown to attenuate morphine mediated 
antinociception (Vaught et al, 1982).
The peptide 5-opioid receptor antagonist ICI 174,864 does not influence morphine-induced 
antinociception per se. However, ICI 174,864 has been shown to antagonise the DPDPE 
and Leu^-enkephalin potentiation and the DAMA and Met^-enkephalin attenuation of 
morphine induced antinociception (Heyman et al, 1989b). This data suggests that the 
modulation of p.-opioid agonist antinociception by 5-opioid agonists is mediated through 5- 
opioid receptors. Further evidence that agonist activity through 5-opioid receptors mediates 
the p-opioid agonist antinociception was provided by the use of selective irreversible 
antagonists (Heyman et a l, 1989a). Pre-treatment of mice with the irreversible p-opioid 
antagonist P-funaltrexamine (p-FNA) did not alter the direct analgesia actions of DPDPE or
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DAMA, however P-FNA pre-treatment prevented the modulation of morphine 
antinociception by both DPDPE and DAMA. In contrast to this finding, pre-treatment with 
another p-opioid receptor antagonist naloxonazine did not influence DPDPE or DAMA 
modulation of morphine antinociception. This finding adds support to a previous report 
that p-FNA binds selectively and irreversibly to the opioid receptor complex (Rothman et 
a l, 1988).
DALCE the irreversible 5-opioid antagonist has been shown to antagonise 5-opioid 
mediated analgesia. However, sub-effective doses of DALCE do not modulate morphine 
antinociception or inhibit 5-opioid agonist modulation of morphine antinociception. 
Together these findings suggests that DALCE binds selectively to the 5noncompiexed-site (5ncx) 
(Jiang et a l , 1990c). In contrast to this another irreversible antagonist 5’NTH has been 
suggested to bind to the 5compiexed-site (5cx), as it inhibits the 5-opioid agonist modulation of 
morphine antinociception but does not antagonise 5-opioid mediated analgesia (Rothman et 
al, 1993).
In addition to the in vivo data there is also considerable in vitro evidence which supports 
the existence of an interaction between p- and 5-opioid receptor binding sites. The first in 
vitro evidence that supported the existence of a p/5 complex was provided from binding 
studies. It was reported that morphine inhibited [^H]Leu^-enkephalin binding in a non­
competitive manner (Rothman and Westfall, 1982). Morphine was shown to inhibit 
[^HJLeu^-enkephalin by reducing the binding capacity and increasing the affinity. 
Mathematical modelling studies demonstrated that this data was best explained by the 
existence of a p and 5 -opioid receptor complex.
[^HJDADLE has been shown to label two binding sites, a high affinity site which p-opioid 
ligands only weakly inhibit and a low affinity site at which p-opioid ligands are potent non­
competitive inhibitors (Rothman et al, 1985). From this data 5-opioid receptor ligand 
binding sites were classified as either being in a complex with the p-opioid receptor 5 cx or
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non-complexed §ncx- The irreversible ligands 2-(4-ethoxybenzyl)-l-diethylaminoethyl-5- 
isothiocyanato benzimidazole (BIT) and N-phenyI-N-[l-(2-(4-isothiocyanato)phenethyl)-4- 
piperidinyl] propanamide (FIT) (Rice et al, 1983) have been reported to selectively deplete 
membranes of the 6 cx- and 6 ncx-receptors respectively (Schoffelmeer et a l, 1988). The 
modulation of 5-opioid receptor binding by p-opioid ligands has been confirmed using FIT 
pre-treated membranes, where morphine non-competitively inhibits [^HJLeu^-enkephalin 
binding at the 5cx-binding site. However, there is little evidence to suggest that 5-opioid 
ligands behave in a parallel but reverse fashion and non-competitively inhibit the binding of 
p-opioid ligands to the p-opioid receptor site of the complex. Leu^-enkephalin and Met^- 
enkephalin have been demonstrated to non-competitively inhibit the maximum binding 
capacity and increase the affinity of [^HJetorphine binding to p-opioid receptors (Rothman 
and Westfall 1982). However, it is known that [^HJetorphine can label both 5 and p-opioid 
receptors, so this finding by Rothman and Westfall (1982) is not conclusive.
In vivo studies have demonstrated that DPDPE and Met^-enkephalin not only modulate the 
potency, but also the efficacy of morphine (Jiang et al, 1990b). This finding suggests that 
the efficacy of morphine could be enhanced in tolerant animals, or in severe nociception by 
the co-administration of sub-effective doses of certain 5-opioid agonists such as DPDPE 
together with morphine. These findings also raise the possibility that co-administration of a 
reduced morphine dose together with a sub-effective dose of 5-opioid agonist, could result 
in equal antinociception as a greater dose of morphine. As the development of tolerance is 
related to dose and exposure time, it is possible that co-administration of morphine (at a 
low concentration) together with a 5-opioid agonist could result in the development of less 
tolerance in chronic morphine treatment.
1.10.2. 5i- and 5?-opioid receptor subtvnes
Further subtypes of 5-opioid receptors have been postulated for several years , the so-called 
5i- and 5 2 -opioid receptor subtypes have been postulated from both in vivo and in vitro 
studies (Jiang et a l, 1991; Sofuoglu et al, 1991a). Results from cross tolerance studies has
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supported the existence of Ô^ - and ôz-opioid receptor subtypes with similar results in both 
mouse and rat models. It has been reported that cross tolerance does not develop between 
DSELT and DPDPE or DPDPE and DELT II (Sofuoglu et a l, 1991a; Mattia et al, 1991c). 
Further evidence for the existence of 6 -opioid receptor subtypes has been provided from 
other in vivo studies, 5'NTH has been demonstrated to antagonise the antinociceptive 
activities of DELT II and DSLET but not that of DPDPE (Jiang et a l, 1991). Naltriben has 
also been demonstrated to be more effective at antagonising the antinociceptive actions of 
DSLET than those of DPDPE and this differential antagonism is more apparent at spinal 
sites as opposed to supraspinal sites (Sofuoglu et a l, 1991a).
DALCE, BNTX, DPDPE and DADLE have been proposed to be 51-selective whereas 
DSLET and deltorphin II are 0 2 -selective (Table 1.3.). Naltrindole and some of its 
analogues, including naltriben and naltrindole-5 '-isothiocyanate (5’NTH) are reported to be 
0 2 -selective (Jiang et al, 1991; Sofuoglu e/ al, 1991a), however naltriben has been shown 
to be more selective than naltrindole at differentiating between the two proposed 6 -opioid 
receptor subtypes (Sofuoglu e / <3/., 1991a).
The existence of 6 -opioid receptor subtypes has been supported by receptor binding studies 
in mouse brain membranes. The maximum binding density (Bmax) of [^HJDSLET has 
been shown to be significantly greater than that of either [^HJDADLE or DPDPE (Sofuoglu 
et al., 1992). In addition a study utilising quantitative autoradiography has suggested a 
different regional distribution of the 6 -opioid receptor subtypes (Hiller et a l, 1995). 
Despite a general similarity between the distribution of binding [^HJDPDPE (6 i) and 
[^HJDSLET (6 2 ) in rat brain sections, some significant differences were noted. Regions 
demonstrating an increase in [^HJDSLET binding compared to [^HjDPDPE binding include 
the amgydaloid nucleus, caudate putamen, nucleus accumbens, hypothalamus and several 
cortical regions including the cingulate and frontal (motor) cortices.
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The non-peptide antagonist 7-benzyidenenaltrexone (BNTX) has been shown to bind with 
100 fold greater affinity to 6 1 - than 6 2 -sites. In addition in the tail flick assay, BNTX was 
shown to antagonise the DPDPE induced-analgesia but not the DSLET induced analgesia 
(Portoghese et al, 1992). However there was not a similar pattern of differential 
antagonism of BNTX on 6 -selective ligands in the mouse vas deferens (MVD). This lead 
to the suggestion that the 6 -opioid receptors in the MVD are distinct from those in the brain 
(Portoghese et al, 1992).
It has been suggested that only the 6 2 -subtype is involved in mediating antinociception at 
spinal sites in mice. In the mouse tail flick assay, 24hour pretreatment with the irreversible 
6 2 -selective antagonist 5'NTH (but not the irreversible 6 1 -selective antagonist DALCE) was 
demonstrated to antagonise the effects of intrathecal injections of either DPDPE or DELT 
II (Mattia et al, 1992). In contrast to this report, both 6 1 - and 6 2 -sites have been shown to 
be involved in the spinal antinociception of 6 -opioid receptor agonists in mice. The 
reversible 6 -selective antagonists BNTX (6 1 -selective) and naltriben (6 2 -selective) have 
been shown to differentially antagonise DPDPE and DELT II respectively (Sofuoglu et a l, 
1993).
The non-selective sulphydryl modifying reagent, N-ethylmaleimide (NEM) has been 
reported to selectively decrease 6 1 -receptor binding. NEM decreased DPDPE binding 
whilst having less of an effect on 6 2 -receptor binding (DSLET) in rat brain membranes 
(Tam and Rafferty, 1994). However the authors fail to consider that the differences in the 
effect of NEM on ligand binding could be due to the ligand differences and not receptor 
subtypes. NEM has been shown to uncouple receptors from G-proteins. The binding of 
different ligands to the same GPCR has been shown to be differently affected by 
uncoupling agents (Kelly et al., 1998). An alternative explanation for the results obtained 
by Tam and Rafferty (1994) could be that the DSLET and DPDPE have different 
selectivities for the 6 -opioid receptor coupled over the uncoupled state. Further studies
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utilising a range of 6 -selective agonists and antagonists would be needed to fully address 
this issue.
It is clear that a vast amount of work has been put into characterising the proposing 6 - 
opioid receptor subtypes. It is difficult to reconcile the more recently proposed 6 i and 6 2 - 
receptor subtypes with the previously suggested 6 cx- and 6 ncx-receptor subtypes (see Table
1.3.). However, to date molecular biology has only identified a single gene encoding the 6 - 
opioid receptor and currently there are no reports of a functional splice variant. The cloned 
6 -opioid receptor has been proposed to be most similar to the 6 2 -opioid subtype (Kong et 
al, 1993). In the case of 6 -opioid receptors the existence of subtypes remains controversial. 
It therefore seems that despite the pharmacological evidence of 6 -opioid receptor subtypes 
an alternative explanation for the data may exist. For example, a single receptor coupled to 
different signal transduction mechanisms may give rise to pharmacological data that is 
suggestive of different receptor subtypes. In addition recent reports of receptor dimers 
resulting in different functional and binding data compared to monomers, provide an 
alternative explanation for the results which were previously conceived to be due to 
receptor subtypes.
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Table 1.3. The reported selectivities of some commonly used 6 -opioid receptor ligands for 
the proposed 6 -opioid receptor subtypes.
Proposed selectivity Reference
Agonist 8i or 82 8cxtfr 8/icx
DPDPE 8 1 8 ncx/8 cx Barret et ah, 1982; Heyman 
et al., 1989.
DELT II Ô2 NR Jiang e/<3/., 1991
DSLET 6 2 8 cx Jiang et al, 1991; Barret et 
a l, 1982; Heyman et al, 
1989.
DADLE 6 1 8 cx Barret et a l , 1982; Heyman 
et al, 1989.
Antagonists
ICI 174,864 NR 8 cx Heyman g/ a/., 1989.
Naltrindole 8 2 NR Sofuoglu et <3/., 1991a; Jiang 
et al 1991
Naltriben 8 2  . NR Sofuoglu et <3/., 1991a; Jiang 
et al 1991
5’Naltrindole 
isothiocyanate
8 2 8 cx Sofuoglu et al 1991a; Jiang 
et al, 1991; Rothman et a l .
BNTX 8 1 NR Portoghese et al, 1992; 
Sofuoglu e/a/., 1993
DALCE 8 1 8 ncx Jiang et a l , 1990c
PPNA NR 8 cx Rothman et a l , 1988
Table 1.3. NR indicates that the selectivity of these compounds for the proposed subtypes 
have not been reported.
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1.11. Aims of Thesis
1. Recently 6 -opioid receptors have been shown to exist as homo- and heterodimers which 
behave differently to 6 -opioid receptor monomers. In addition 6 -opioid receptor are known 
to couple to several G-protein subtypes. In light of these recent findings it is possible that 
ligands with different selectivities for the different 6 -opioid receptor states may give rise to 
data which has been previously interpreted as being indicative of 6 -opioid receptor 
subtypes. This study therefore aims to characterise the selectivities of 6 -opioid receptor 
ligands for the G-protein coupled and uncoupled states of the 6 -opioid receptor.
2. Mice lacking the p-opioid receptor have been reported to have a partial loss of some 6 - 
opioid receptor mediated responses. In order to further characterise this phenomenon this 
study determined the effect the absence of the p-opioid receptor has on the G-protein 
coupling of 6 -opioid receptors in the brains of mice lacking the p-opioid receptor.
3. The binding of the 6 -opioid receptor agonists [^H]SNC-121 and [^H]R-Atc-Ile^’^  
deltorphin II have been reported to behave atypically to the presence of GTP analogues. 
This purpose of this investigation was to further characterise the effect of both [^H]SNC- 
121 and [^H]R-Atc-Ile^’^  deltorphin II at the mouse 6 -opioid receptor.
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Chapter 2
Characterisation of the selectivities of 0-opioid 
receptor ligands for the G-protein coupled and 
uncoupled 5-opioid receptor states.
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2.1. Introduction
ô-Opioid receptors belong to the G-protein coupled receptor (GPCR) superfamily. Ions 
and GTP analogues have been known for many years to regulate ligand binding to GPCR’s. 
GTP and its analogues, including the non-hydrolysable guanylylimidodiphoshpate 
(GMPPNP) uncouple G-proteins from receptors forcing the receptor into a state which has 
decreased affinity for agonists and increased or unchanged affinity for antagonists (i.e. R 
state, see Section 1.9.). The binding of non-hydrolysable GMPPNP to the a-subunit of the 
G-protein effectively prevents the regeneration of the G-protein trimer and therefore results 
in the accumulation of the uncoupled receptor state (Wong et a l , 1994). Sodium ions also 
decrease agonist binding, though the mechanism of this effect is less well characterised. An 
intracellular site of action for the effect of sodium ions on agonist binding has been 
proposed as the concentration of sodium required to decrease agonist binding was shown to 
be less than the extracellular concentration of sodium (Zajac et a l, 1990). Sodium ions and 
GTP analogues have been suggested to influence ligand binding via different mechanisms. 
Opioid receptors purified in the presence of sodium ions (IM) were proposed to be 
functionally coupled to G-proteins as the GTP analogue GTPyS reduced agonist binding, 
further purification of the receptors uncoupled the receptors from G-proteins (Li et a l,  
1992). Ligand binding of the G-protein uncoupled receptors was shown to be sodium 
sensitive (Li et a l, 1992). A single residue of GPCR’s has been proposed to be responsible 
for the effect of sodium ions on ligands binding. An aspartate residue of the second 
transmembrane spanning region is highly conserved in different GPCR’s, this residue has 
been suggested to be responsible for sodium regulation of both 8 -opioid and a^- 
adrenoceptor ligands (Horstman et a/., 1990; Kong et a l , 1993).
The influence of cations and GTP analogues on 8 -opioid receptor binding has been the focus 
of much work. Early studies demonstrated that guanine nucleotides and sodium ions 
specifically decreased opioid agonist binding in both brain membranes (Blume, 1978a; 
Childers and Snyder, 1979) and membranes prepared from NG108-15 cells (a mouse
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neuroblastoma-glioma hybrid which endogenously expresses 5-opioid receptors) (Blume, 
1978b; Chang et al, 1981). Opioid receptor antagonist binding has been reported to 
increase in the presence of sodium ions (Pert et al, 1973). GTP and its analogues have been 
shown to decrease 5-opioid receptor agonist binding predominantly by increasing agonist- 
dissociation rates (Werling et al, 1984; .Zajac and Roques, 1985) (for a review of the 
influence of GTP analogues and sodium ions on 5-opioid ligand binding the reader is 
directed to Cox, 1993).
Recently some reports have been published that show the binding of some 5-opioid 
receptor agonists have atypical responses to the presence of GTP analogues and sodium. 
The binding of the non-pep tide 5-opioid agonist BW373U86 has been suggested to be 
largely insensitive to the presence of both GTP analogues and sodium in rat and mouse 
brain, (Childers et a l, 1993; Wild e/ a l, 1993c), mouse vas deferens (Wild et al, 1993c) 
and neuroblastoma cell lines (Childers et al, 1993). This apparent insensitivity to GTP 
analogues and sodium is in contrast to the agonist activity that BW373U86 displays at 
the 5-opioid receptor (Chang et a l, 1993; Wild et a l, 1993b). Binding of the 
BW373U86 related agonist, SNC-80, has als.o been reported to be atypical. pHjSNC- 
80 binding to cloned human 5-opioid receptors is decreased by sodium but not by the 
GTP analogue GMPPNP (Knapp et a l, 1996). In addition, there is some conflict in the 
literature regarding the effect of GTP analogues and sodium ions on the binding of the 
reduced form of SNC-80, SNC-121. The affinity and apparent receptor density of 
[^H]SNC-121 binding in the presence of GMPPNP and sodium ions has been reported to be 
either unaffected (Knapp et al., 1996) or slightly decreased (Ni et al, 1995) compared to 
control. [^H]SNC-121 has been shown to bind to the 5-opioid receptor in a different 
manner than peptide opioid ligands (Li et al, 1995). It has been proposed that this different 
binding is responsible for the atypical responses of GTP analogues and sodium ions on the 
binding of the SNC series of agonists (Knapp et al, 1996).
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This suggestion is in contrast to a recent finding that suggests a deltorphin II analogue 
(RATGLU) is also insensitive to the presence of GMPPNP. Despite being a potent 
agonist (subnanomolar IC50 in the mouse vas deferens (Toth et a l ,  1997)), and 
structurally unrelated to the SNC compounds, the binding of [^HJRATGLU to rat brain 
membranes was unchanged by GMPPNP but decreased by sodium ions (Kelly et a l ,  
1998). This apparent anomaly between the potent agonist activity of RATGLU and 
the atypical binding profile could be e?qplained by the existence of either a species or 
tissue difference in the 5-opioid receptor. However, if, as previously discussed (Section 
1.9.) a more complex model than the two state receptor model exists, the binding data of 
[^H]SNC-121 and RATGLU may not be in contrast to their agonist actions.
To further characterise the atypical binding profile of [^H]SNC-121 and pH]RATGLU, 
the effect of GMPPNP and sodium were studied in mouse brain membranes. These 
results were directly compared and contrasted with the effect of GMPPNP and sodium 
on the binding of a typical 5-opioid agonist and antagonist (pH]deltorphin I and 
[^Hjnaltrindole respectively). Additionally, in preparation for a further study to 
investigate the coupling of 5-opioid receptors in different brain regions, quantitative 
autoradiography was used to determine the effect of GMPPNP on the binding of the 
same pH]5-op ioid ligands in mouse brain sections . A previous autoradiography study 
by our laboratory (unpublished data) has suggested that the inclusion of Na"^  ions in the 
incubation buffer does not affect [^H]deltorphin I binding in mouse brain sections. This 
finding, which is in contrast to the result seen with homogenate binding was attributed to 
the presence of sodium ions in the pre-incubation buffer (>100mM, see Section 2.2.2.5.) 
Consequently in the current autoradiography study only the effect of GMPPNP on the 
binding of the [^ H] 5-opioid ligands was investigated.
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2.2. Materials and Methods
2.2.1. Homogenate Binding
2.2.1.1. Animals
Male Balb/C animals were used in all experiments. The animals were allowed free 
access to standard rat chow diet (B&K Universal Ltd.) and water. Animals were, 
housed at a constant temperature of 22 ±1°C, humidity of 45-55% and on a 12 hour 
light dark cycle (lights on at 0700 hrs, off at 1900 hrs)
2.2.1.2. Brain isolation and membrane preparation
Mice were killed by cervical dislocation. Brains were removed (minus cerebella), 
weighed and placed in ice cold Tris HCl (50mM, pH 7.4@0°C) and were transported to 
the laboratory in ice. Brains from 15 mice were pooled and homogenised in 40 volumes 
of buffer (ice cold Tris HCl, 50mM, pH 7.4@0°C) using a Kinematica Polytron (speed 
4 for 45s). The homogenate was centrifuged at 49,000g for 15 minutes at 4°C (Beckman 
L5-65B Ultracentrifuge). The supernatant was discarded and the resulting pellet 
resuspended in 100 volumes Tris HCl (50mM, pH 7.4@37°C). The suspension was 
divided into 4 equal aliquots and incubated in a shaking water bath (Julabo SW, 80/min) 
for 45 minutes at 37°C to remove endogenous opioids. The suspension was 
recentrifuged and the resulting pellet was suspended at a concentration of lOmg original 
wet weight/ml in Tris HCl (50mM, pH 7.4 at the subsequent incubation temperature) 
to yield a crude membrane suspension. For pH] SNC-121 experiments the membrane 
pellet was resuspended in Tris HCl containing bacitracin (100p.g/ml), bestatin 
(lOpg/ml), leupeptin (4pg/ml) and chymostatin (2p.g/ml). For experiments to 
investigate the effect of sodium ions on the binding of [^H]radioligand, the crude 
membrane suspension was divided in half and sodium chloride (final concentration 
lOOmM) was added to one half of the membrane suspension.
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2.2.1.3. Radioligand binding
Saturation binding curves (consisting of 10 concentrations) were constructed for 
[^H]deltorphin I (0.1-9nM), [^HJRATGLU (0.2-6nM), [^H]SNC-121(0.2-20nM) and 
[^H]naltrindole (0.01-lnM). Saturation binding was determined in triplicate for each 
concentration used. From one membrane preparation, four saturation binding curves for 
one ligand was determined, i.e. under control conditions (50mM Tris HCl), in the 
presence of GMPPNP (50p,M), in the presence of sodium ions (lOOmM) and in the 
presence of both GMPPNP (50pM) and sodium ions (lOOmM). In addition for 
pH] deltorphin I saturation curves were constructed in the presence of increasing 
concentrations of GMPPNP (10-200p.M). Each assay was performed a minimum of 5 
times.
For all ligands, receptor binding incubations had a final volume of 2ml comprising the 
following;- 1.9ml crude membrane suspension (at a density of lOmg wet weight/ml) 
either with or without sodium ions (lOOmM), varying amounts of radioactive ligand 
(10-80pl) and Tris HCl buffer (pH 7.4 @ incubation temperature) to make the 
incubation mixture up to 2ml. In all cases the addition of the [^H]radioligand was the 
final addition to the incubation mixture and therefore initiated the start of the incubation 
time. For incubations that were to include GMPPNP (50p.M), GMPPNP (20|il of 
5mM) was added to the membrane suspension 30minutes before the addition of the 
radioligand. For [^H]deltorphin I incubations that were to include different
concentrations of GMPPNP (either 10, 100, or 200p,M GMPPNP), the appropriate 
additions of stock GMPPNP (either 5mM or 20mM) were made to the membrane 
preparation 30 minutes prior to the addition of [^H]deltorphin I.
For all saturation curves a parallel set of three tubes containing naloxone (lOjiM) were 
prepared to determine non-specific binding (NSB) for each concentration of
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[^H]radioligand. The reactions were incubated in a shaking water bath (Julabo SW, 
80/min) for a pre-determined period of time and temperature; [^HJdeltorphin I and 
[^H]RATGLU 60 minutes @ 37°C, [^HJSNC-121 120minutes @ 25°C and 
[^HJnaltrindole 90minutes @ 25°C.
The incubations were terminated by filtration under vacuum using a Brandel Harvester 
with presoaked Whatman GF/B glass fiber filters (1% polyethylenimine Tris HCl 
buffer (50mM, pH 7.4@0°C) for 2hrs). The membranes were washed three times with 
4ml of ice-cold Tris HCl buffer (pH 7.4@0°C). The individual filters (plus membranes) 
were placed in scintillation vials and tissue solubilizer (0.5ml of 10%Triton X-100 in 
toluene) and scintillation fluid (5ml Unisolve E) was added to all tubes. Bound 
radioactivity was determined a minimum of 17hrs later by liquid scintillation using a 
Rackbeta II scintillation counter, each vial was counted over a 5minute period. Aliquots 
(lOjil) of the stock solution of [^H]radioligand were also counted in order to determine 
the exact concentration of the incubation mixtures and a [^HJhexadecane standard was 
counted on each occasion to establish the efficiency of the counter.
2.2.1.4. Protein analysis
Protein concentration of all samples of membrane homogenates was determined by a 
method based on Lowry (1951).
Samples were retained and stored at -20°C for a maximum of 12 weeks. Samples were 
thawed and diluted 1:1 in Tris HCl buffer (pH 7.4 @ 25°C) to a level of 5mg original 
wet weight/ml. To the diluted membrane sample (0.5ml), 2.5ml of freshly prepared 
reagent (9Sparts 2%w/v sodium carbonate (in O.lMNaOH), Ipart 2%w/v cupric 
sulphate and Ipart l%w/v potassium sodium tartrate) was added. The mixture was 
vortexed and left to stand for lOminutes, after which time 0.25ml Folins/Ciocalteus 
phenol reagent (diluted 1 : 1  with distilled water) was added and the mixture revortexed.
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The colour was allowed to develop for 30minutes before the optical density of the 
sample was determined at 690nm against a Tris/reagent/Folins blank. 0.5ml samples 
were assayed in triplicate against a bovine serum albumin standard curve (50-500|ig 
protein/ml). A minimum correlation coefficient of r^=0.95 was required for assay 
acceptability.
2.2.1.5. Data analysis and statistical procedures
The saturation binding data were fitted to one- and two-site models by non-linear 
regression analyses using the curve fitting program Prism (Graphpad Software, San 
Diego, CA). All data are from a minimum of 5 experiments. One factor analysis of 
variance (ANOVA) was performed for evaluating the effects of GMPPNP on ligand 
binding.
2.2.2. Autoradiographv binding
2.2.2.1. Animals 
See section 2.2.1.1.
2.2.2.2. Cleaning and gelatin-coating ofmicroscope slides
Slides (74 x 26mm) (Marienfeld, Germany) were soaked overnight in a hot detergent 
(Decon) and warm water solution. The following day, the detergent was discarded and 
the slides were rinsed under hot running water for 15minutes followed by a further 
15minutes under cold distilled running water. Slides were then soaked for 30minutes in 
a ethanolihydrochloric acid solution (90:10v/v) before being rinsed again with cold 
distilled running water. Slides were then coated with gelatin by dipping each slide into a 
1% gelatin/chrome-alum solution for 2 minutes. Slides were allowed to dry in a dust- 
free environment before use.
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2.2.2.3. Brain isolation
Mice were killed by cervical dislocation and intact whole brains removed immediately. 
Brains were rapidly frozen in isopentane (maintained between -20 and -30°C) for 30 
seconds. Brains were transported back to the laboratory in dry-ice and stored at -70°C 
for no more than a month before sectioning.
2.2.2.4. Brain sectioning
Brains were transferred to a cryostat (Zeiss Microm 505E) set to -20°C for sectioning. 
Sections were thaw mounted onto ice-cold, pre-cleaned gelatin coated microscope 
slides. Slides were stored on ice until completion of sectioning of each brain. A total of 
36 adjacent coronal (20pm) sections were cut from each brain (starting at Bregma co­
ordinates 1.42mm taken from the mouse brain atlas of Franklin and Paxinos, 1997). 
These sections were utilised in a variety of experiments. Adjacent sections were either 
used to determine saturation binding of [^HJdeltorphin I in the presence or absence of 
GMPPNP (50pM) or the effect of increasing concentrations of GMPPNP (10-200pM) 
on the binding of [^HJdeltorphin I or [^HjRATGLU.
Adjacent brain sections were also used for determination of total binding, binding in the 
presence of GMPPNP and non-specific binding (NSB) for each of [^H]SNC-121 and 
[^HJnaltrindole. Some additional adjacent sections were cut for determination of total 
[^H]SNC-121 binding and [^H]SNC-121 binding in the presence of either GMPPNP 
(lOpM), naloxone (lOpM) or both nociceptin (10p.M) and naloxone (lOpM).
Following sectioning slides were transferred into sealed plastic containers containing 
anhydrous calcium sulphate (Drierite) for dehydration purposes. The containers were 
stored a 4°C for two hours (to prevent the formation of ice crystals) before being 
transferred to a freezer (-20°C for a minimum period of one and a maximum of four 
weeks) prior to [^Hjradioligand binding.
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2.2.2.5. Radioligand binding
(i) For determination of the effect of GMPPNP (50pM) on [^H]0-opioid ligand binding 
brain sections for total binding, binding in the presence of GMPPNP and NSB were 
processed together using identical [^HJradioligand stock solutions. All slides were 
allowed to defrost at room temperature for SOminutes prior to binding. All slides were 
preincubated for SOminutes in Tris HCl (50mM) and NaCl (0.9% w/v) buffer (pH 7.4 
@ 25°C) to remove bound endogenous opioids. Slides were then placed into binding 
trays and solutions for the determination of total binding, binding in the presence of 
GMPPNP and NSB applied at a volume of 0.96ml per slide. Radioligand stocks were 
made up on the day of binding in an incubation buffer of Tris HCl (50mM, pH 7.4 @ 
25°C) (except for [^HJnaltrindole, incubation buffer composed as above but with the 
inclusion of bovine serum albumin (0.1%) and magnesium chloride (5mM)). 
Radioligand stocks for the determination of total binding, binding in the presence of 
GMPPNP (50pM) and NSB were made up at the following concentrations 
[^H]deltoiphin I, 7nM; [^H]SNC-121, lOnM, pHJRATGLU, 4nM and 8 nM and 
[^HJnaltrindole 0.4nM and InM. Concentrations for each ligand was chosen as it 
represented 3-4 times Kd of the ligand at the 5-opioid receptor as previously 
determined in this laboratory or in the literature. Stocks for determination of NSB of all 
ligands contained naloxone (lOpM).
Following the incubation time (pre-determined either by our laboratory or the literature) 
of:- [^HJdeltorphin I and [^HJRATGLU, 60minutes; [^H]naltrindole, 90minutes and 
[^H]SNC-121, 120minutes, the slides underwent 3 x 5minute washes in ice-cold Tris 
HCl buffer (50mM, pH 7.4 @ 0°C). Slides were then dried for two hours under a cold 
air stream, before being placed in a sealed plastic container with drierite (for further 
dehydration) for a minimum of 5 days.
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The concentration of [^HJradioligand stocks was confirmed by liquid scintillation 
counting. Samples (lOpl) of stock solutions were placed in scintillation vials together 
with Scintillant fluid (5ml, Unisolve E) and were counted a minimum of IThours later 
using a Rackbeta II scintillation counter.
(ii) For determination of the effect of increasing concentrations of GMPPNP on 
[^HJdeltorphin I and [^H]RATGLU binding to mouse brain sections, radioligand binding 
was carried out as detailed above (Section (i)) except that four concentrations of 
GMPPNP (10, 50, 100 and 200p.M) were used on slides containing adjacent brain 
sections.
(iii) For determination of the effect of GMPPNP on the affinity of [^HJdeltorphin I, 
radioligand binding was carried out as detailed above (Section 2.2.2.5.) except that 8  
different concentrations (between 1-16nM) of [^HJdeltorphin I, was used in the 
presence and absence of GMPPNP (50|xM).
(iv) For determination of the effect of both nociceptin and naloxone on the binding of 
[^ H] SNC-121, radioligand binding was carried out as detailed above (Section (i)) except 
that the incubation buffer was Tris (50mM), EGTA (0.2mM), MgCl] (3mM), 
bacitracin (2 0 pg/ml) and bovine serum albumin (0 .1 %) and an additional slide including 
[^H]SNC-121, naloxone (10p,M) and nociceptin (lOpM) was processed alongside the 
[^H]SNC-121 total binding, binding in the presence of GMPPNP and NSB slides.
2.2.2.6. Laying o f autoradiography film
Slides for autoradiography analysis were laid down against card with [^Hjmicroscale 
standards (low: 2.7-216 Bq/mg, High: 53-239 Bq/mg estimated tissue equivalent, 
Amersham) which served as tritium standards. All slides for a single experiment were 
laid on the same card. The card was secured inside hypercassettes and [^H]sensitive
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hyperfilm (both purchased from Amersham) was laid emulsion side down directly onto 
the tissue sections and microscale standards (in a darkroom under safe light conditions 
(red filter)). The hypercassettes were additionally sealed (against light leakage) around 
the edges with opaque insulation tape. All films were apposed for a period of 5 weeks 
before development.
2.2.2.7. Development o f autoradiography film
Following the five weeks exposure films were developed under dark room conditions. 
Films were placed in a developing tray, emulsion side up in Kodak D19 
developeridistilled water solution (50:50) for three minutes. Development was stopped 
by placing the films in a tray containing a stop solution (comprising distilled water and 
3 drops of glacial acetic acid) for 30seconds. Films were then fixed in a tray containing 
Kodak Rapid Fix (pre-made according to manafacturers instructions) for 2minutes. 
During development of films, all trays were gently rocked to ensure even coverage of 
the film by the solutions. The films were then rinsed in fresh distilled running water for 
2 0 minutes, before being air-dried in a dust free environment.
2.2.2.8 . Image analysis o f autoradiography film
Quantitative analysis of autoradiography films was carried out using video-based 
computerised densitometry employing an MCID image anlyser (Imaging Reasearch, 
Canada). Receptor binding was expressed as fmol/mg tissue equivalent as determined 
by reference to the [^HJmicroscale standards. Specific binding was determined by 
subtraction of NSB from the total binding or binding in the presence of GMPPNP. 
Measures were taken from both left and right hand sides of the brain for each region, 
values therefore represent a duplicate measurement. Only four regions were analysed 
and these were chosen for their high levels of 6 -opioid binding; regions analysed were 
superficial and deep layers of the rostralsomatosensory cortex and the lateral and medial 
caudate putamen (Bregma co-ordinates 1.10mm, mouse brain atlas of Franklin &
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Pakinos, 1997). Sampling tools were used to establish binding densities for each region, 
measurements were taken using a free hand drawing tool for the caudate and a box tool 
(8 x 8  pixel) for the cortex.
2.2.2.9. Data analysis and statistical procedures
For each [^H]5-opioid ligand, a value for the mean and S.E.M. specific binding was 
generated for all brain structures analysed and for each treatment group. The percentage 
change in binding induced by GMPPNP was determined from specific binding for each 
region analysed. The time course and saturation binding data were fitted to one- and 
two- site models by non-linear regression analyses using the curve fitting program 
Prism (Graphpad Software, San Diego, CA). All data are from a minimum of 3 
experiments. For statistical purposes one factor analysis of variance (ANOVA) 
followed by Fishers post hoc test (GBStat) was performed for evaluating the effects of 
GMPPNP on ligand binding.
2.2.3. Materials
2.2.3.1. Radioactive chemicals
[^HJNaltrindole (44.2Ci/mmol) and [^HJRATGLU (36Ci/mmol) were generous gifts 
from Hungarian Academy of Sciences, Szeged. [^HJDeltorphin I (47Ci/mmol) was 
custom synthesised by Amersham Radiochemicals and pH]SNC-121 (53Ci/mmol) was 
purchased from TOCRIS.
2.2.3.2. Non radioactive chemicals
Naloxone hydrochloride, bovine serum albumen and Folins reagent were purchased from 
Sigma chemicals, GMPPNP was purchased from Roche Diagnostics and nocicieptin 
was purchased from Bachem. Chymostatin, bacitracin and bestatin were purchased
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from Sigma and leupeptin was purchased from Amersham. All other chemicals used 
were of analytical grade.
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2.3. Results
2.3.1. HomogenateBinding
2.3.1.1. Control Binding
[^HJDeltorphin I, [^H]SNC-121, [^HJnaltrindole and [^HJRATGLU bound to mouse brain 
membranes with high affinity and in a saturable manner (Table 2.1.). In contrast to the 
peptide radioligands, saturation of [^H]SNC-121 binding could only be achieved in the 
presence of peptidase inhibitors. Analysis of the saturation curves (using the curve fitting 
program, GraphPad Prism) demonstrated that the binding of all ligands fit significantly 
better to a one site than a two site binding model. There was a significantly greater number 
of binding sites recognised by [^Hjnaltrindole and [^HJRATGLU compared to either 
[^H]deltorphin and pH]SNC-121 (1 way ANOVA, P<0.05) (Table 2.1.).
2.3.1.2. Effect ofGMPPNP on the binding o f [^HJdeltorphin I  [^HJRATGLU, [^HJSNC-121 
and [^HJnaltrindole
GMPPNP (lOjiM) did not have a significant effect on the binding of [^HJdeltorphin I. 
GMPPNP (50-200pM) did significantly decrease [^H]deltorphin I maximum binding 
without significantly changing affinity of the ligand (Fig 2.1.) (1 way ANOVA P<0.05). 
GMMPNP (50p.M) had a maximal effect on [^HJdeltorphin I. binding (Fig. 2.1.). The 
saturation binding curve of [^H]deltorphin I in the presence of GMPPNP (50p.M) was 
shown to fit significantly better to a one site model than a two site model. [^H]SNC-121, 
[^HJnaltrindole and [^HJRATGLU binding affinity and density was unaffected by the 
inclusion of GMPPNP (50pM) in the incubation buffer (Table 2.1.)
2.3.1.3. Effect o f Sodium ions on the binding o f [^HJdeltorphin I, [^HJRATGLU, [^HJSNC- 
121 and j^HJnaltrindole
The inclusion of sodium chloride (lOOmM) in the incubation buffer of [^HJdeltorphin I, and 
[^HJRATGLU caused a significant decrease in the maximalbinding of the ligands without a 
change in the affinity of the ligand (Table 2.1.). There was no specific binding of [^H]SNC-
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Table 2.1. Effect of GMPPNP and Na"^  on the binding of [^H]deltorphin I, [^H]RATGLU, 
[^H]SNC-121 and [^HJnaltrindole binding in mouse brain membranes (Balb/C).
Ligand Experimental
conditions
Bmax (fmol/mg 
protein)
Kd
[^HJDeltorphin I Control 93.7 ±4.0 1.21 ±0.09
(n=9)
GMPPNP (50pM) 81.9 ±4.9* 1.33 ±0.09
Na^(lOOmM) 35.8 ±4.7** 1.83 ±0.13
Na^(lOOmM) & 
GMPPNP (50pM)
37.2 ±4.3** 4.32 ±2.10
[^HJRATGLU Control 129.1 ±8.1 0.98 ±0.11
(n=6 )
GMPPNP (50pM) 124.8 ±12.6 1.18 ± 0 . 2 2
Na-"(100mM) 41.8 ±4.0** 0.83 ±0.13
Na '^ClOOmM) & 
GMPPNP (50|iM)
37.6 ±3.7** 0.96 ± 0.37
[^H]SNC-121 Control 79.7 ± 7.7 4.73 ± 0.92
(n=6 )
GMPPNP (50pM) 73.6 ± 6.4 5.5 ±0.67
Na^(lOOmM) ND ND
Na+(100mM) & 
GMPPNP (50pM)
ND ND
[^H]Naltrindole Control 126.4 ± 9.2 0.25 ± 0.04
(n=5)
GMPPNP (50jiM) 138.9 ±17.0 0 .2 2 ± 0 . 0 2
Na + (100mM) 155.5 ± 19.5 0 .2 0 ± 0 . 0 2
Na+(100mM) & 
GMPPNP (50pM)
141.4 ±13.0 0.18 ± 0 . 0 1
Values represent means and S.E.M. Significant differences compared to control are marked 
* (P< 0.05) and ** (P<0.01). ND represent values that were not detectable.
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Figure 2.1. The effect of increasing concentrations of GMPPNP on the binding of [^ H]
deltorphin I to mouse brain membranes.
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Fig. 2.2. The effect of either GMPPNP or Na  ^or both on the maximum binding
of various [^H]5-opioid ligands in mouse brain membranes (Balb/C).
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121 in the presence of sodium chloride (lOOmM) (Table 2.1.). The percentage decrease in 
[^H] deltorphin I binding induced by sodium ions (lOOmM) was significantly greater than 
the decrease induced by GMPPNP (50pM) (1 way ANOVA, P<0.05) (Fig. 2.2.). In contrast 
to control binding and binding in the presence of GMPPNP (50piM) there was not a 
significant difference in the number of sites recognised by [^H]deltorphin I compared to 
[^HJRATGLU (Table 2.1.). The inclusion of sodium chloride (lOOmM) did not 
significantly effect the binding of [^HJnaltrindole (Table 2.1.).
The inclusion of both sodium chloride (lOOmM) and GMPPNP (50jiM) did not have a 
significantly greater effect on the binding of [^H]deltorphin I, [^H]SNC-121 and 
[^HjRATGLU than the inclusion of sodium chloride (lOOmM) alone (Table 2.1 and Figure
2.2.). Furthermore there was no significant effect of including GMPPNP (50pM) and 
sodium chloride (lOOmM) on the binding of [^HJnaltrindole. In all instances the saturation 
binding curves of the ligands in the presence of sodium chloride (lOOmM) fit significantly 
better to a one site than a two site model.
2.3.2. Autoradio graphv
The distribution of [^H]Deltorphin I, [^H]SNC-121, [^H]RATGLU and [^HJnaltrindole 
control binding was identical (Fig. 2.6.). [^H]Deltorphin I (7nM) recognised significantly 
more binding sites than [^HJnaltrindole (InM), [^H]SNC-121 (lOnM) and [^H]RATGLU 
(4nM) (Table 2.2. and 2.3.). The non specific binding of [^H]SNC-121 (determined in the 
presence of lOjiM naloxone) showed regional differences in density. This residual binding 
of [^H]SNC-121 was unchanged by the presence of nociceptin (lOpM) (Fig. 2.10).
GMPPNP (10-200pM) did not have a significant effect on the binding of [^H]RATGLU 
(4nM) in any brain regions quantified (Table 2.2 and Fig. 2.3.) at either of the 
concentrations of [^H]RATGLU used (4nM and 8 nM) (Figs. 2.8. and 2.9.). GMPPNP (10- 
200pM) caused a concentration dependent decrease in the binding of [^H]deltorphin I in all 
regions quantified, with 50pM having maximal effect (Table 2.2. and Fig. 2.3.). The
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decrease in [^H]deltorphin I binding was shown to be due to a significant loss of binding 
sites and not reduced affinity (Table 2.4). GMPPNP (50pM) significantly decreased 
[^H]SNC-121 binding in all regions of the brain quantified (Table 2.3. and Fig. 2.6.). The 
GMPPNP (50p,M) induced decrease of [^H]SNC-121 binding was significantly greater than 
the decrease induced in [^H]deltorphin I binding (Figs. 2.4., 2.6. and 2.7.). There was not a 
regional variation in the effect of GMPPNP (SOpM) on the binding of either [^H] deltorphin 
I or [^H]SNC-121 (Figs. 2.4. and 2.7.).
[^H]Naltrindole binding (0.4 and InM) was significantly increased by the inclusion of 
GMPPNP (50pM) in the incubation buffer (Fig. 2.7., 2.8., 2.9. and Table 2.3.). In contrast 
to the results with the 6 -opioid agonists, there was a regional variation in the effect of 
GMPPNP (50jiM) on [^HJnaltrindole binding with a greater change apparent in the caudate 
compared to the cortex (Fig. 2.7., and 2.9.). This finding was similar at both of the 
concentrations of [^HJnaltrindole studied (Fig. 2.8. and 2.9.).
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Fig. 2.7. The effect of GMPPNP (50jiM) on pH]SNC-121 and pH]naltrindole binding
in mouse brain sections.
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Fig. 2.9. Comparison of the effect of GMPPNP on the binding of different concentrations
of [^H]naltrindole and [^HJRATGLU
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2.4. Discussion
Throughout this study the effects of GMPPNP on the binding of all of the [^H]5-opioid 
ligands is greater when assessed using autoradiography than homogenate binding. This 
finding is supported by other reports which suggest that using autoradiography small 
changes in receptor numbers and coupling can be detected that are not apparent in whole 
membrane binding (Park et a l, 2000). It is feasible that the process of homogenisation 
irreversibly uncouples some of the GPCR’s. This would result in fewer coupled receptors 
in membrane preparations compared to sections and hence a smaller GMPPNP induced 
shift. In both the autoradiography and homogenate binding studies maximal effect of 
GMPPNP was seen at (SOpM), this concentration was therefore used to compare the effect 
that GMPPNP had on the binding of all the [^H]5-opioid ligands. Due to the non- 
hydrolysable nature of GMPPNP, it was assumed that at this concentration all GPCRs were 
uncoupled and any binding of the ligands was to the uncoupled receptor state.
The binding of the selective 5-opioid receptor agonist [^HJdeltorphin I was decreased by 
GMPPNP in a concentration dependent manner in both autoradiography and homogenate 
binding. In contrast to previous reports this decrease in binding is shown to be due to a loss 
of receptor binding sites and not due to decreased affinity of the ligand (Blume, 1978a; 
Childers and Snyder, 1980). This finding is hard to reconcile with Leff s two state model 
(Leff, 1995). In contrast to the other 5-opioid agonists the binding of [^HJRATGLU to 
mouse brain was seen to be insensitive to the presence of GMPPNP (up to 200p.M) in both 
autoradiography and homogenate binding, whilst sodium ions did decrease the binding of 
[^H]RATGLU. This finding is in agreement with a previous study which showed a similar 
binding profile of [^HJRATGLU in rat brain membranes (Kelly et a l, 1998). More 
evidence for [^H]RATGLU behaving differently to other 5-opioid agonists is given by the 
greater number of binding sites detected with [^H]RATGLU compared to either 
[^HJdeltorphin I or [^H]SNC-121. [^HJRATGLU recognised the same number of binding 
sites as the antagonist [^H]naltrindole, this finding suggests that there may be a 5 -opioid 
receptor state that is recognised by [^HJRATGLU and [^HJnaltrindole but not
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[^HJdeltorphin I and [^HJSNC-121. This data does not support the two state receptor model 
(Leff, 1995), as the data suggests that [^H]RATGLU has no selectivity for R* over R and 
therefore should be an antagonist and not an agonist. This is clearly in contrast to its potent 
agonist activity at the mouse vas deference (IC50 <lnM) (Toth et a l, 1997). This could be 
explained if, as previously suggested, there is a difference between the peripheral 0 -opioid 
receptor and the central 5-opioid receptor (Vaughn et a l, 1990). However, the binding of 
other agonists (e.g. the D2 receptor agonists, ergopeptines) have also been reported to be 
insensitive to the presence of guanyl nucleotides (Sibley and Creese, 1983) and an 
explanation for this finding has recently been proposed (Strange, 1998). Incorporating the 
extended ternary complex model (Lefkowitz et a l, 1993), Strange argued that agonist 
binding can be insensitive to the presence of GTP analogues if the agonist stabilises a form 
of the receptor, in the absence of G-protein coupling, that is similar to the conformation of 
the ternary complex (ligand-receptor-G-protein). If RATGLU does stabilise this 
intermediary form of the receptor, it is possible that [^HJRATGLU may act as a partial 
agonist at the 5-opioid. It is unclear from the report by Toth et a l (1997) if RATGLU 
causes complete inhibition of the twitch of the field stimulated mouse vas deferens. Partial 
agonists can be identified from them having sub maximal effects at a given receptor 
however, if a tissue has a large receptor reserve this effect may not be apparent. Further 
work is needed to clarify the functional effects of RATGLU at the 5-opioid receptor.
In contrast to the results obtained using mouse brain membranes, GMPPNP 
significantly increases the binding of [^HJnaltrindole in mouse brain sections. This 
would suggest that [^HJnaltrindole has a higher affinity for the uncoupled receptor than 
the coupled receptor and that [^H]naltrindole may behave as an inverse agonist at the 5- 
opioid receptor. Previously [^Hjnaltrindole binding has been reported to be unaffected 
by the inclusion of sodium ions and GTP analogues and suggested to act as a pure 
antagonist (Merkouris et a l, 1997; Szekers and Traynor, 1997; Kelly et a l, 1998). In 
contrast the 5-opioid antagonist ICI-174,684 is now widely accepted to behave as an 
inverse agonist in various cell systems which exhibit constitutive activity of 5-opioid
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receptors (Georgoussi and Zioudrou, 1993; Merkouris et a l ,  1997; Neilan et a l ,  1999). 
However, in support of the current study [^HJnaltrindole has been shown to behave 
similarly to [^H]ICI 174,684, with binding being increased in the presence of GMPPNP 
and sodium ions (Rogers et a l ,  1990). These differences in the effect of [^HJnaltrindole 
may be due to different methodology or species differences in the 6 -opioid receptor. 
However other 6 -opioid ligands have been reported to have different activities when the 
receptor is expressed in different systems. The selective 6 -opioid ligand naltriben has 
been reported to be either a pure antagonist (Szekers and Traynor, 1997) or an inverse 
agonist (Neilan et a l ,  1999). The activity of a ligand at a receptor varies in different 
cell lines depending on the assay system, the basal activity of the receptor and the level 
of receptor and G-proteins expression, therefore it would appear that [^Hjnaltrindole 
may behave as a inverse agonist in some systems. The data in the current study suggests 
that there may be a regional difference in the effects of GMPPNP on the binding of a ligand 
as GMPPNP induces a bigger shift in [^H]naltrindole binding in the caudate compared to 
the cortex. A recent study has suggested that there is a regional difference in the efficiency 
of the coupling of p-opioid receptors in rat brain (Maher et al , 2000). Utilising membranes 
prepared from discrete brain regions the authors suggest that there is not a direct correlation 
between the expression of p-opioid receptors and the level of activation by agonists. The 
present study suggest that this also may be true of 6 -opioid receptor, but a more thorough 
study, quantifying more regions is needed before this can be concluded.
In agreement with a previous finding the binding of [^H]SNC-121 to mouse brain 
membranes was found to be insensitive to the presence of GMPPNP (Knapp et al , 1996) . 
However, in the current study it was not possible to detect any specific binding of 
[^H]SNC-121 binding to mouse brain membranes in the presence of sodium chloride 
(lOOmM). This finding is in contrast to the study by Ni et al., (1995) who reported that 
sodium ions only partially reduced the affinity (but not the receptor density) of [^H]SNC- 
121 binding to rat brain membranes. Furthermore, again in contrast to Ni et aï. (1995) 
the current study demonstrated that [^H]SNC-121 equilibrated with the 6 -opioid
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receptor in under two hours. In the autoradiography study GMPPNP (50pM) was shown 
to have a greater effect on the binding of [^H]SNC-121 compared to [^Hjdeltorphin I. This 
f i n d i n g  suggests that [^H]deltorphin recognises more of the uncoupled receptors than 
[^H]SNC-121, suggesting that [^H]SNC-121 is a more efficacious agonist at the 6 -opioid 
receptor than [^H]deltorphin I. This finding is supported by previous reports that 
demonstrate SNC-series agonists to be more efficacious than some peptide agonists (Clark 
et a l, 1997; Fraser et al, 1999).
In common with other reports this study found that [^H]SNC-121 has a high level of NSB 
(Knapp et al, 1995; Ni et al, 1995). Despite the inclusion of excess naloxone (lOpM) in 
the incubation buffer of autoradiography studies, the residual [^H]SNC-121 binding (50- 
70% of total binding) appeared to be localised to the regions normally expressing the 6 - 
opioid receptor. [^H]SNC-121 has a slow dissociation rate firom the 6 -opioid receptor, once 
bound forming a very stable complex (Knapp et al, 1996). It is therefore feasible that the 
sections should have been pre-incubated with naloxone before the addition of [^H]SNC- 
121, to ensure that the ligand does not bind to the 6 -opioid receptor. [^H]SNC-121 has also 
been reported to bind to a different domain of the 6 -opioid receptor than the peptide ligands 
such as deltorphin I (Ni et al, 1995). SNC-121 has a unique binding interaction with a 
single amino acid residue (Trp^ "^^ ) compared to deltorphin I, pCl-DPDPE or naltrindole 
binding (Li et a l, 1995). In addition, it has been recently demonstrated that the human 6 - 
opioid receptor is differently down regulated by SNC-80 than DPDPE (Okura et a l, 2000). 
It is clear that there are differences in the way in which the peptide and non-peptide 
agonists recognise and activate the 6 -opioid receptor, it is therefore possible that either a 
higher concentration of naloxone or a different antagonist is needed to fiilly displace the 
[^H]SNC-121 binding from the 6 -opioid receptor.
It is clear that there are a number of anomalies with the NSB of [^H] SNC-121. Non­
specific binding is normally due to the ligand binding to something other than a receptor. It 
has been previously been postulated that residual [^H]SNC-121 binding is not due to non­
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specific binding but rather it labelling a non-opioid binding site (Ni et a l ,  1995). This 
proposed non-opioid binding site of [^H]SNC-121 and related compounds have been poorly 
characterised to date. In contrast to other non-peptide opioid ligands, SNC-121 and related 
compounds contain a piperizine moiety. Other ligands with a piperizine moiety include the 
dopamine receptor antagonists, fiuphenazine and fiupenthixol; the 5HT-agent buspirone 
and the a  receptor ligand rimcazole. Ni et a l  (1995) demonstrated that despite the 
structural similarities between SNC-121 and some dopamine-, 5HT- and a-receptor 
ligands, that the non-opioid binding of [^H] SNC-121 was not displaced by either dopamine 
antagonists (clozapine and chlorpromazine), a 5HT antagonist (metergoline) or a-ligand 
(pentazocine), suggesting that the non-opioid binding site of [^H]SNC-121 is not either a 
dopamine, 5HT or a-opioid receptor. The current study has furthered this research, from 
the distribution of the residual [^H]SNC-121 binding it appears to bind to a receptor that 
has a diffuse localisation. Due to the structural homology between the ORL-1 receptor and 
the opioid receptors (Mollereau et al ,  1994), the diffuse pattern of distribution of the ORL- 
1 receptors in the brain (Sim and Childers, 1997) and the naloxone insensitive binding of 
the ORL-1 endogenous ligand, nociceptin (Calo et a l , 1997) the effect of nociceptin on the 
residual [^H]SNC-121 binding was investigated. Cold nociceptin did not displace the 
residual [^H]SNC-121 binding and it can therefore be concluded that the residual binding of 
[^H]SNC-121 is not to the ORL-1 receptor. The inclusion of GMPPNP did not displace the 
residual binding of [^H]SNC-121 suggesting that the non-opioid binding site is not a G- 
protein coupled receptor. Finally, despite the non-peptide structure of SNC-121 and in 
contrast to the peptide ligands ([^H]deltorphin I and [^HJRATGLU) it was impossible to 
obtain a saturation of [^H]SNC-121 binding in mouse brain membranes in the absence of 
peptidase inhibitors (data not shown). Previous studies investigating the binding of 
[^H]SNC-121 to rat brain membranes (Ni et al ,  1995) have also included peptidase 
inhibitors when using the ligand. This finding together with the distribution of the residual 
[^H]SNC-121 binding suggests that there may be a protein associated with binding to the Ô- 
opioid receptor. A recent study has reported that there is an accessory protein for binding
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to the dopamine receptor (Lezcano et a l, 2000). Further work is needed to clarify the 
nature of the residual [^H]SNC-121 binding.
In conclusion, this study provides evidence that both homogenate binding and 
autoradiography are suitable methods to characterise 6 -opioid receptor coupling. 
Autoradiography is a more sensitive technique than homogenate binding and is a suitable 
method to characterise regional changes in 6 -opioid receptor coupling. Data from the 
current study supports the existence of a more complex GPCR model than the two state 
model proposed by Leff (1995). This study has also provided more evidence that the 6 - 
opioid ligand [^H]SNC-121 has a binding site that is localised to areas expressing 6 -opioid 
receptors but distinct to opioid receptors. This atypical binding site of [^H] SNC-121 in not 
at the ORL-1 receptor nor does it appear to bind to a G-protein coupled receptor. Finally 
data in this study suggest that [^Hjnaltrindole and [^H]RATGLU may behave as an inverse 
agonist and partial agonist (respectively) at the mouse 6 -opioid receptor.
90
Chapter 3
Characterisation of the functional responses of 
naltrindole and RATGLU at 8-opioid receptors
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3.1. Introduction
3.1.1. Inverse agonists
Antagonists were classically thought to inhibit agonist activity by binding to receptors 
without activating them and thereby preventing agonist binding and thus activation (see 
Section 1.9). The first evidence that an antagonist could produce the opposite effect to an 
agonist and not merely inhibit agonist binding was provided from ion channel receptors. In 
contrast to other benzodiazepines, the benzodiazepine methyl 6,7-dimethoxy-4-ethyl-P- 
carboline-e-carboxylate (DMCM) has been shown to be a potent convulsant in vivo 
(Braestrup et a l, 1982). Again in contrast to other benzodiazepines, DMCM was also 
shown to bind preferentially to the non-GABA-stimulated conformation of the GABAa 
receptor (Braestrup et al, 1982). This finding lead to the suggestion that the GABA- 
benzodiazepine ion channel could exist in equilibrium between two conformations, an open 
(active) and a closed (inactive) channel form. DMCM was proposed to have high affinity 
for the closed channel and thus stabilise this form, resulting in decreased binding of G ABA 
to the active form of the receptor (Braestrup et al, 1982). The term inverse agonist has 
been adopted to describe ligands that have greater affinity for the inactive receptor state and 
therefore pull the equilibrium between the receptor states away from the active receptor 
state.
G-protein coupled receptors have also been shown to exist in an equilibrium between two 
receptor states. Some 6 -opioid antagonists (including ICI 174,864) were demonstrated to 
have negative intrinsic activity in NG108-15 cell membranes (Costa and Herz, 1989). They 
also demonstrated that inverse agonists such as ICI 174,864 had a greater affinity for 6 - 
opioid receptors after the cell membranes were treated with N-ethylmaleimide (which 
uncouples GPCR’s). These findings suggest that in these membranes some 6 -opioid 
receptors are pre-coupled to G-proteins under basal conditions (i.e. in the absence of ligand) 
and therefore show constitutive activity. Since this report, there have been several reports 
of ICI 174,864 behaving as an inverse agonist at 6 -opioid receptors in other cell line 
membranes including C6  glioma cells (Neilan ef a/., 1999) and Rat 1 fibroblasts (Mullaney 
and Milligan, 1996). ICI 174,864 has also been reported to act as an inverse agonist in
92
intact cell lines including human embryonic kidney 293 cells (Chiu et al , 1996) and RAT 1 
fibroblast cells (Merkouris et al , 1997). The effect of ICI 174,864 has been demonstrated to 
be pertussis toxin sensitive, implicating the involvement of the G; and Gq proteins (Chiu et 
<2 /., 1996; Mullaney and Milligan, 1996).
Many other GPCR’s have been demonstrated to exhibit constitutive activity including P- 
adrenoceptors, a-adrenoceptors, 5-hydroxytryptophan and dopamine receptors. A number 
of inverse agonists have been identified from studies utilising systems in which receptors 
show constitutive activity (see Milligan et a l , 1995). Since the emergence of the concept of 
inverse agonists, it has been proposed that neutral antagonists (i.e. pure antagonists) are 
either extremely rare or do not really exist (De Ligt et al, 2000). It has been suggested that 
ligands with exactly the same affinity for different receptor conformations seems unlikely, 
what is more probable is that there is a range of activities from full agonists to full inverse 
agonists. Furthermore, it has become apparent that the activity of a ligand depends on 
many factors in addition to the receptor states, including receptor density and in the case of 
receptors which can couple promiscuously to different G-proteins, the relative expression 
of G-protein subtypes (Kenakin, 1995; Zemig and Saria, 1999).
There is a great deal of pharmacological evidence that demonstrates G-protein coupled 
receptors can express basal activity in cell lines. Studies utilising such cell lines have 
identified a number of ligands that behave as inverse agonists. However what is unclear 
from these studies, is whether inverse agonists and constituitively active receptors have a 
physiological or patho-physiological role. A recent review by De Ligt (2000) discusses the 
evidence supporting the existence of in vivo constitutively active receptors, the discovery 
of endogenous inverse agonists and the effect of long term inverse agonist treatment. For 
instance there have been suggestions of upregulation of ^-adrenoceptors and possibly H] 
histamine receptors by long term inverse agonist treatment (see De Ligt et a/;.2000). 
Receptor mutations leading to constitutively active receptors have been reported in some 
disease states including familial male limited precocious puberty, autosomal dominant
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hypoparathyroidism and retinitis pigmentosa (Spiegel, 1996). It has been proposed that 
inverse agonists may provide an effective treatment for such conditions.
3.1.2. Partial agonists
Full agonists are classically characterised as ligands that produce maximal effect at a 
receptor, whereas those that produce less-than-maximal effect are called partial agonists. 
The term efficacy relates to the maximal ability of a drug-receptor complex to evoke a 
response in a cell or tissue. Partial agonists have been suggested to have varying amounts of 
efficacy depending on the extent of receptor reserve. 3-PPP (R(+)-3-(3-hydroxyphenyl)-N- 
propylpiperidine) a dopamine agonist has been shown to be selective for presynaptic D2- 
receptors compared to postsynpatic D2-receptors. This effect has been reported to not be 
due to receptor subtypes, but rather the presence of a greater pre-synaptic receptor reserve. 
Similar results have also been demonstrated for 5HT receptors (for a review see Hoyer and 
Boddeke, 1993). The measurement of maximal effects of ligands is therefore of limited 
value because partial agonists behave as antagonists when receptor reserve is low and full 
agonists when receptor reserve is high. Utilising NG108-15 cells receptor expression has 
been determined to influence the intrinsic activity of partial agonists. Partial agonists had 
greatest intrinsic activity in cell lines that expressed more receptors (Clark et a l, 1999). 
Kosterlitz and Watt (1968) first described a method to determine partial agonist activity in 
isolated tissues. Kosterlitz and Watt (1968) postulated that all opioid ligands could act 
either as an agonist or antagonist depending on what other ligands were also present in the 
preparation.
Partial agonists have been proposed to induce less receptor desensitisation than full agonists 
(for review see Clark et a l, 1999). The rate of desensitisation of GPCR’s is largely 
dependent on phosphorylation of the receptor by GRK’s (see Section 1.7). Partial agonists 
have been suggested to stabilise a conformation of the receptor that has a lower capacity to 
bind GRK’s than the receptor conformation induced by full agonists. This suggestion is 
supported by reports that morphine is a partial agonist at the 6-opioid receptor and does
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not induce internalisation of the receptor (Keith et ah, 1996). Despite this it is clear that 
morphine does cause tolerance and dependence and would therefore appear to down 
regulate the receptor via a different mechanism.
3.1.3. Microphvsiometrv
A microphysiometer can be used to detect and monitor the response of live cells to a 
variety of chemical substances, including ligands for specific cell surface receptors. The 
microphysiometer measures subtle changes in the extracellular basal acidification rate 
(BAR). The BAR is dependent on the metabolic state of cells (through excretion of acidic 
metabolites such as lactic acid and carbon dioxide) the homeostasis of intracellular pH 
(through the regulation of proton transport across the cytoplasmic membrane) and from 
changes in cell energy demand during receptor and ion channel activation (Parce et a l , 1989; 
McConnell et al , 1992) (Fig. 3.1.).
The most commonly used microphysiometer is the Cytosensor (Molecular Devices). One 
of the major advances of using microphysiometry is that it enables real-time monitoring of 
the response of living cells, which can be either a primary cell culture from tissues (Raley- 
Susman et al , 1992; Trafton et al , 1996) or cloned cell lines, which express a pure target 
receptor by molecular biological manipulation (Coldwell e/ al ,  1999; Ng et a l ,  1999; Wood 
et al ,  1999). As the changes in extracellular acidification rate are downstream from the 
primary stimulus and signal transduction events the Cytosensor can be used to measure the 
response to a ligand regardless of which intracellular pathway is activated. Indeed, 
microphysiometry can be used whether a single or multiple signalling pathways are 
activated (McConnell et aï., 1992). The ubiquitous nature of changes in extracellular rate in 
cellular metabolism has also allowed many different receptor systems and signalling 
pathways to be studied. Activation of a wide variety of receptors has been characterised 
using microphysiometry including G-protein coupled receptors (Owicki et aï., 1990; 
Coldwell <2 /., 1999; Taniguchi e/ a/., 1999; Wood et aï., 1999), growth factor receptors
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(Pitchford et al, 1995) and ligand-gated ion channel receptors (Raley-Susman e/ al , 1992; 
Trafton e /<2 /., 1996).
Several studies have shown that microphysiometry is a viable method to characterise 
receptor pharmacology, yielding results for both agonists and antagonists that are consistent 
with the accepted pharmacology for a range of receptors, including, human dopamine 
receptors (Coldwell et al , 1999), corticotrophin-releasing factor receptors (Smart et al ,  
1999) and secretin receptors (Ng et al, 1999). Microphysiometry has also been used to 
demonstrate that ICI 174,864 behaves as an inverse agonist activity at the 6-opioid receptor 
(Merkouris et al,  1997).
In order to further characterise the atypical binding profiles of naltrindole at the 6-opioid 
receptor (see Chapter 2) microphysiometry was used to determine if naltrindole behaved as 
an inverse agonist in intact cells. In addition the field stimulated mouse vas deferens 
bioassay was used to determine if RATGLU could act as a partial agonist against other 6- 
opioid agonists.
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Fig 3.1. Schematic representation of the production of acidic metabolites by a cell.
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Fig. 3.2. Schematic representation of a) microphysiometer chamber and b) 
microphysiometry experiment protocol.
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3.2. Materials and Methods
3.2.1. Field stimulated mouse vas deferens assay
3.2.1.1. Animals 
See section 2.2.1.1.
3.2.1.2. Tissue isolation and mounting
Mice were killed by cervical dislocation and the abdomen opened to expose the testes and 
vasa deferentia. The vasa deferentia were freed from the epidydmis and cut as near to the 
junction with the prostate as possible. Tissues were placed in a beaker containing 
magnesium free Kreb’s solution (of the following composition NaCl (118mM), NaHCOs 
(25mM), glucose (25mM), KH2PO4 (1.2mM), KCl (4.8mM) and CaCb (2.5mM)) at room 
temperature. The connective tissue and closely adhering blood vessels were dissected 
gently from the vasa deferentia. Semen from within the vasa deferentia was expelled by 
rolling the tissue gently between the fingers.
A length of cotton was tied to each end of the tissue to allow connection of one end of the 
tissue to a tissue holder and the other end to a transducer. Both threads were tied as near as 
possible to the end -of the vas deferens so a maximum length of tissue was available for 
stimulation. The tissue was transferred to a 5ml organ bath containing magnesium free 
Kreb’s solution (composition as above) at 36°C and aerated with 95%/5% O2 and CO2 . 
Isometric contractions of the vas deferens were recorded by attaching the vas deferens to a 
Grass FT03 transducer which was connected to a Grass polygraph. The tissue was placed 
under 300mg tension and allowed to equilibrate for 30 minutes with frequent washes.
Following the equilibration period the vas deferens was field stimulated via two linear 
platinum electrodes 0.5cm apart. Stimulation was achieved using a Grass stimulator and 
the following parameters; twin pulses of 70V, a delay of 75ms, a duration of 1ms and a 
frequency of 0.1 Hz. The tissues were allowed to stabilise for a minimum of 15 minutes 
with washes every 5 minutes.
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3.2. L3. Determination o f agonist potency
Concentration response curves to either deltorphin I, SNC-121 or RATGLU were 
determined on each tissue. Drugs were added to tissues cumulatively, in quarter log 
concentrations until complete inhibition of twitch height was achieved. Each new dose was 
added to the tissue after the response of the tissue to the previous response had stabilised 
(4-5 twitches of the same height). After maximal response had been achieved, the tissues 
were washed three times and the tissues allowed to recover for 30 minutes (with washes 
every 5 minutes) before a second concentration response curve was constructed. In some 
tissues naltrindole (lOnM) was added to the bath 30 minutes before the start of the second 
concentration response curve.
3.2.1.4. Determination ofpartial agonist activity o f RATGLU
The method used to determine the partial agonist activity of RATGLU was based on the 
method described by Kosterlitz and Watt (1968). The vasa deferentia from a single animal 
were used, one vas deferens as a control tissue and the other as the test tissue. After the 
control stimulation period (see Section 3.2.1.2.) a concentration of deltorphin 1 known to 
cause maximal inhibition of the twitch height was added to both tissues to confirm tissue 
viability. The tissues were washed 3 times and left to recover for 30 minutes with washes 
every 5 minutes. A concentration of RATGLU known to produce approximately 20% 
inhibition of the twitch height (0.02nM) was added to the test tissue. After the response to 
RATGLU had plateaued (5-lOminutes) a concentration of either deltorphin 1 (0.0InM) or 
SNC-121 (40nM) that caused approximately 50% inhibition of the control twitch height 
was added to both tissues.
3.2.1.5. Data manipulation and statistical procedures
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For concentration response curves, the percentage inhibition of the control stimulated 
twitch induced by a concentration of drug was plotted against the log bath concentration of 
drug and non-linear analysis was carried out using Graphpad Prism to determine the 
concentration of agonist causing 50% inhibition (IC50). Each value represents a mean and 
confidence intervals (95%) of at least 3 experiments. For statistical purposes paired 
Student t-test were used.
3.2.1. Microphvsiometrv
Chinese hamster ovary (CHO) cells stably expressing the recombinant human 8 -opioid 
receptor were grown as monolayers on Falcon cell culture vented flasks (75cm^) and 
maintained under 5% CO2 at 37°C. Cells were cultured in growth media (Hams F12 
nutrient mixture supplemented with foetal calf serum (FCS) (10%), L-glutamine (2mM), 
penicillin (100,000units/litre) and streptomycin (lOOmg/litre) (pen-strep) and hygromycin 
(2.5mg/litre)). Cells were passaged every 3-4 days using the following method; the cell 
monolayer was washed with 2 x 1 0ml of pre-warmed sterile Dulbecco’s phosphate buffered 
saline (PBS) (37°C). Cells were then treated with Cell Dissociation Solution (3ml) to 
detach the monolayer from the flask. The flasks were agitated and then replaced in the 
incubator for 10-15 minutes to enable maximum detachment. To the cell suspension 7ml of 
pre-warmed growth media was added and the cells seeded in 2 0 ml of growth media at an 
approximate final density of 1 x 1 0  ^cells per flask.
Prior to the experiment (18-24hours) cells at approximately 80% confluency were washed 
with Dulbecco’s PBS and detached from the culture flasks with Cell Dissociation Solution 
as detailed above. Cells were resuspended in Cupping Media (RPMI media supplemented 
with FCS (10%), L-Glutamine (2mM) and pen-strep (100,000 units/litre and lOOmg/litre 
respectively). Cells were subsequently seeded into microphysiometer cups (pore size 3p.m, 
diameter 12mm) at a density of 200,000 cells per cup. Cells were maintained under 5% 
CO2 at 37°C before the start of the experiment (18-24hours). On the day of the experiment 
a spacer and capsule insert were placed into each cup and the assembled cups were loaded
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a spacer and capsule insert were placed into each cup and the assembled cups were loaded 
into the microphysiometer chambers maintained at 37°C (Fig. 3.2.). Cells were then left to 
establish a stable baseline acidification rate (BAR) for at least 50 minutes whilst being 
perfused with Running Media (low buffering bicarbonate free RPMI 1640 supplemented 
with L-glutamine (2mM), pen-strep (100,000units/litre and lOOmg/litre respectively) and 
NaCl (24mM) (pH 7.4 at 37°C)) (at a flow rate of 120pl/min). Total perfusion cycle was 
2 minutes, the pumps were on for the first 80 seconds, media flow was then halted for the 
next 2 0  seconds allowing the media bathing the cells to acidify according to cellular 
metabolic rate. The basal acidification rate was determined over a period of 30seconds from 
8 8  to 118 seconds (Fig. 3.3.).
The effect of deltorphin I, RATGLU, SNC-121, naloxone, naltrindole and ICI 174,864 on 
the basal acidification rate was determined. Concentration response curves to each drug 
were constructed with drugs perfused over the cells for 10 minutes. Drugs were diluted to 
the desired concentration in Running Media and a maximum of 8  drug concentrations were 
used. A 30 minute recovery period was allowed between each concentration of drug tested. 
In a single experiment each drug was added to two chambers and the mean of the responses 
of the two chambers was taken as the result for an individual experiment to the drug. Some 
chambers were not exposed to any drugs in order to determine the effect of time on the 
basal acidifcation rate. Each experiment was repeated a minimum of 6  times. The effect 
of pre-incubation of the cells with naloxone (lOpM) was determined on the responses of 
naltrindole, ICI 174,864, deltorphin I, RATGLU and SNC-121.
To control for variations in basal acidification rates between populations of cells in 
different chambers, responses were subsequently normalised with respect to the baseline 
point immediately before agonist addition and are expressed as percentage increase or 
decrease over basal acidification rate.
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3.2.1.3. Materials
Low buffering bicarbonate free RPMI 1640, microphysiometer cups, spacers and capsule 
inserts were purchased from Molecular Devices. Dulbecco’s phosphate buffered saline, 
Hams F12 nutrient mixture, RPMI 1640, Cell Dissocation Solution, L-glutamine, and pen- 
strep were purchased from SIGMA. Hygromycin and fetal calf serum were purchased from 
GIBCO Brl and PAA laboratories respectively. ICI 174,864, deltorphin I, SNC-121 were 
purchased from Sigma, Bachem and Tocris respectively. CHO cells stably expressing 
recombinant human 6 -opioid receptors originated from the laboratory of Yamamura 
(Malatynska et al., 1996) and were provided for the current study by Pfizer Central 
Research, Kent (Clone hDOR/pREP 10#2-209-2).
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3.3. Results
3.3.1. Field stimulated mouse vas deferens
RATGLU, deltorphin I and SNC-121 decreased the twitch height of the field stimulated 
mouse vas deferens in a concentration dependent manner (Fig. 3.3.). Deltorphin I, SNC- 
121 and RATGLU caused complete inhibition of the twitch height of the field stimulated 
mouse vas deferens (MVD). Deltorphin I and RATGLU were at least 40 fold more potent 
than SNC-121 at inhibiting the twitch of the field stimulated MVD (IC50 of deltorphin I, 
0.36nm (95% C.I. 0.26 -  0.53nM); RATGLU 0.17nM (95% C.I. 0.08 -  0.41nM) and 
SNC-121 13.23nM (95% C.I. 11.09 -  16.66nM). Pre-incubation of the MVD with 
naltrindole (lOnM) caused a 100 fold parallel shift to the right of the concentration 
response curve of RATGLU (Fig. 3.3 ). Two consecutive concentration response curves to 
deltorphin I and RATGLU could be constructed on the same tissue, however only one 
concentration response curve to SNC-121 could be constructed on each tissue (data not 
shown).
Pre-incubation of the MVD with RATGLU (0.02nM) significantly inhibited the response of 
the MVD to deltorphin I (O.lnM) (Fig. 3.4.). In contrast to this finding, pre-incubation of 
the MVD with RATGLU did not significantly effect the response to SNC-121 (20nM) (Fig.
3.4.).
3.3.2. Mirophvsiometrv
RATGLU, deltorphin I and SNC-121 caused a concentration dependent increase in BAR 
(Fig. 3.5a.). Deltorphin I and RATGLU were shown to be at least 50 fold more potent at 
increasing the BAR compared to SNC-121. Preincubation of the cells with naloxone 
(lOpM) prevented the agonist induced increase in BAR (Fig. 3.5a). Increasing 
concentrations of naloxone (up to IpM) did not change the BAR compared to control (Fig. 
3.5b). In contrast increasing concentration of naltrindole and ICI 174,864 caused a 
concentration dependent decrease in BAR (Fig. 3.5b.). The maximum inhibition of BAR
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was similar for both naltrindole and ICI 174,864 (Fig. 3.6.). Preincubation of the cells with 
naloxone (10|xM) inhibited the naltrindole and ICI 174,864 decrease in BAR (Fig. 3.6.),
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Fig. 3.3. Concentration response curves of RATGLU, deltorphin I and
SNC-121 in the field stimulated mouse vas deferens.
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Fig. 3.4. The effect of RATGLU on deltorphin I and SNC-121 induced
inhibition of twitch height of the field stimulated mouse vas deferens.
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Fig. 3.5. The effect of 8 -opioid ligands on the basal acidification rate of CHO cells stably 
expressing the recombinant human 8 -opioid receptor.
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Fig. 3.6. The effect of naltrindole and ICI 174,864 in the presence and absence of 
naloxone (10p.M) on the basal acidification rate of CHO cells stably expressing the 
recombinant human 5-opioid receptor.
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3.4. Discussion
This study demonstrates that naltrindole has inverse agonist characteristics in CHO cells 
stably expressing the recombinant human 6 -opioid receptor. This finding suggests that 
naltrindole has greater selectivity for the uncoupled 6 -opioid receptor state. In agreement 
with this finding, naltrindole binding is significantly increased in the presence of GMPPNP 
in mouse brain sections (See Chapter 2). However in contrast to this finding, naltrindole 
has been suggested to have partial agonist activity in NG108-15 cells (Szekers and Traynor, 
1997) and to be a pure antagonist in C6  glioma cells (Neilan et al, 1999). It has been 
proposed that p-adrenoceptor ligands may demonstrate positive, negative or neutral effects 
on receptor activity depending on the assay system used (Chidiac, 1995). The conflicting 
actions of naltrindole at 6 -opioid receptors in different systems does not support the two 
state receptor model (Leff, 1995).
In contrast to the varying effects of naltrindole, ICI 174,864 has been reported to behave as 
an inverse agonist in many assay systems (Costa and Herz, 1989; Chiu et a l, 1996; 
Mullaney and Milligan, 1996; Szekers and Traynor, 1997; Neilan et a l, 1999). This 
suggests that ICI 174,864 may have greater efficacy as an inverse agonist than naltrindole. 
In agreement with this suggestion ICI 174,864 has been previously reported to be an 
inverse agonist with high efficacy (Mullaney and Milligan, 1996). However in contrast to 
this suggestion the present study demonstrates ICI 174,864 and naltrindole inhibit the BAR 
to similar extents. This finding may suggest that microphysiometry is not a suitable 
method for determining the efficacy of inverse agonists. Alternatively the results of the 
present study which suggest ICI 174,864 and naltrindole having equal efficacy as inverse 
agonists may be due to the cell line utilised for these experiments. Manipulation of the 
receptor expression of the cells may increase spontaneous activity of the 6 -opioid receptors 
and thus provide a bigger window to characterise efficacy of inverse agonists.
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RATGLU causes complete inhibition of twitch height in the field stimulated mouse vas 
deferens. This finding suggests that RATGLU behaves as a full agonist according to the 
classical definition. However, this is in clear contrast to the binding study that 
demonstrates RATGLU having equal affinity for the uncoupled and coupled 6 -opioid 
receptor states (see Chapter 2).
Pre-incubation of the mouse vas deferens with RATGLU significantly attenuates the 
deltorphin I induced inhibition of twitch height. In contrast pre-incubation of the mouse 
vas deferens with RATGLU did not significantly effect the SNC-121 induced inhibition of 
twitch height. This finding gives rise to an intriguing possibility that RATGLU antagonises 
the effect of deltorphin I but not SNC-121. As previously discussed (see Section 2.4.) 
SNC-121 is known to bind to the 6 -opioid receptor differently to the peptide agonists, other 
differences in the binding of SNC-121 have also been reported including a slow 
dissociation rate and greater efficacy than peptide 6 -opioid receptors. It is therefore 
possible that the different interaction of SNC-121 with the 6 -opioid receptor may be 
responsible for the different effect of RATGLU on the deltorphin I and SNC-121 induced 
inhibition of the twitch height of the field stimulated mouse vas deferens.
An alternative explanation to this finding is that deltorphin I and RATGLU are acting at 
different 6 -opioid receptor subtype than SNC-121. However this is thought to be unlikely, 
the vas deferens has been reported to express a homogenous 6 -opioid receptor population 
(Wild et al, 1993a) and SNC-121 has been suggested to bind to both 6 i- and 6 2 -opioid 
receptors (Ni et al, 1995).
In conclusion this study demonstrates that microphysiometry is a suitable method for 
characterisation of agonist and inverse agonist actions of 6 -opioid receptor ligands. This 
study also provides support for naltrindole and RATGLU behaving as an inverse agonist 
and a partial agonist (respectively) at the 6 -opioid receptor. These findings are in support
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of the results from binding studies of both naltrindole and RATGLU previously described 
(Chapter 2).
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Chapter 4
Characterisation of the G-protein coupling of 8-opioid 
receptors in brains of p-opioid receptor knockout mice.
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4.1. Introduction
The first opioid receptor to be disrupted using transgenic approaches was the p-opioid 
receptor. No gross anatomical deficits were apparent in the animak and normal 
development, w ei^ t g^in and maternal behaviour were reported (Matthes et a l, 1996). 
There are now 5 groups that have rep orted the successful generation of mice lacking the 
p-op ioid receptor (pKO) (Matthes et ah, 1996; Tian et al ,1997; Sora et a l , 1997a; Loh 
et a l ,  1998; Schuller et a l ,  1999). Homologous recombination has been utilised in the 
generation of all of these mice, but different exons of the p-op ioid receptor gene have 
been targeted. In all cases disruption of the p-op ioid receptor gene leads to a complete 
loss of the main biological actions of morphine, including analgesia, reward, 
immunosuppression, constipation and tolerance (Matthes et a l ,  1996; Sora et a l ,  
1997b; Loh et a l ,  1998; Matthes et a l ,  1998). Morphine lethaUty is also absent in 
pKO animals (Loh et al, 1998). A tonie role for the p-op ioid receptor in the regulation 
of basal gastrointestinal (GI) motility has also been suggested as pKO mice have 
reduced GI basal activity (Roy et a l ,  1998). The role of the p-op ioid receptor in the 
modulation of pain sensitivity is more debatable, some groups have reported no 
alterations in pain sensitivity (Matthes et a l ,  1996), whilst others have reported 
hyperalgesia (Sora et al, 1997a) or hypoalggsia (Qui et a l ,  1998; Sora et a l ,  1999). 
This apparent conflict in the literature is probably due to different studies beingutlised. 
For a more detailed review of the current literature published on the pharmacology and 
behavioural phenotype of pKO mice the reader is directed to Kieffer (1999) and 
Kitchen, (1999).
Overall there are no major compensatory changes in either k -  or 6 -opioid receptors in 
pKO animals (Matthes et al, 1996; Loh et al, 1998). However there have been some 
indications in the literature that there are some subtle changes in both the ejq)ression and 
function of the 6 -opioid receptor in pKO mice. In contrast to the results from 
membrane binding studies (Matthes et al, 1996) quantitative autoradiography has
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demonstrated a small but significant decrease in the number of [^HJdeltorphin I binding 
sites in some brain regions of pKO mice. The brain regions demonstrating this down 
regulation are predominantly non-cortical areas that are known to have a high e)g)ression 
of p-op ioid receptors in wildtype animals (Kitchen et al, 1997).
In agreement with this finding of discrete changps in the 6 -opioid receptor in pKO 
animals, Matthes et al, (1996) reported that administration of the selective 6 -opioid 
receptor agonist BUBU ([Tyr-D-Ser(OtBu)-Gly-Phe-Leu-Thr(OtBu)]) did not cause 
antinociception in the tail flick test in pKO animals whereas it caused significant 
antinociception in wildtype animals. Furthermore it has also been reported that other selective 
6 -opioid ligands (i.e. [D-Pen^, D-Pen^]enkephalin and deltorphin II) have partially reduced 
activity in pKO animals, including complete absence of respiratory depression and 
reduced analgesia in the tail flick model (Sora et a l, 1997b; Matthes et a l, 1998).
These findings of altered 6 -opioid agonist mediated effects in pKO mice could be 
e^ g) laine d if the 6 -opioid agonists used require a low level of p-op ioid receptor 
occupation to elicit maximal response. Alternatively, if a functional p/ 6  complex exists 
as suggested (Vau^t et al, 1982; Rothman et al, 1988) (see Section 1.4.2.) it is feasible 
to assume that the lack of antinociceptive responses in pKO animals to certain 6 -opioid 
agonists could be e?g)lained by the removal of the p-op ioid receptor from the comp lex. 
The remaining 6 -opioid receptor may have an altered signal transduction pathway, 
regulation or G-protein coupled state.
To address this issue several groups have investigated the G-protein coupling of the 6 - 
opioid receptor. Matthes et al, (1998) reported that the ability of 6 -opioid agonists to 
stimulate p^SJGTPyS binding in pKO mice brain membranes was unchanged compared 
to wildtype. A more recent study has also assessed the ability of various 6 -opioid 
ligands to stimulate [^^SJGTPyS binding in the brains of pKO animals (Hosohata et a l.
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2000). The maximal response of pCl-DPDPE was shown to be reduced, whereas the 
potency and maximal responses of DPDPE, [D-Ala^,Glu'^]deltorphin and SNC-80 were 
unchanged in pKO mice compared to wildtype. Intracerebroventricular injection of DPDPE 
produced dose-related antinociception in wildtype and this antinociception was 
significantly reduced in pKO mice. In contrast, deltorphin II was equipotent at inducing 
analgesia in both wildtype and pKO’s. The authors suggested that it is only the effects of 
DPDPE and its close structural analogues that are changed in pKO mice. They conclude 
that the 5-opioid receptor remains functionally coupled to the G-protein and that the signal 
transduction pathway is not significantly altered in the absence of the p-opioid receptor 
(Hosohata era/., 2000). They postulate that the anomalous finding with DPDPE and pCl- 
DPDPE (i.e. reduced maximal effect in animals lacking the p-opioid receptor and loss of 
antinociception) can be explained by these agonists inducing antinociceptive activity via a 
low affinity interaction with the p-opioid receptor in wildtype mice. This suggestion is in 
contrast to the earlier findings that report reduced responses in pKO mice of 6 -opioid 
agonists structurally unrelated to DPDPE, e.g. BUBU, deltorphin II and [^H]deltorphin I 
(Sora et a l, 1997b; Matthes et al., 1998). Furthermore, after intraperitoneal injection of 
acetic acid, the non-peptide 6 -opioid agonist SNC 80 has been shown to reduce writhing in 
wildtype but not pKO mice (Sora et al, 1999).
In contrast to the findings from membrane binding studies which suggest 6 -opioid receptors 
remain functionally coupled in pKO mice (Matthes et a l, 1998; Hosohata et a l, 2000) a 
recent autoradiography study has reported no DPDPE induced stimulation of [^^SJGTPyS 
binding in either the caudate or cerebral cortex in pKO mice (Park et a l, 2000). Park et a l  
(2 0 0 0 ) suggested the p-opioid receptor is needed for functional 6 -opioid receptor coupling. 
This hypothesis would mean that 6 -opioid agonists do not have any effect in mice lacking the 
p-opioid receptor, which is in clear conflict to the reported functional data (Matthes et a l, 
1998; Loh et al, 1998; Hosohata et al, 2000). Only three brain structures were quantified in 
the autoradiographic study (Park et al, 2000), so it is unclear what the effect of the absence
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of the p-opioid receptor has on the coupling of the 6 -opioid receptor throughout the brain. It 
is possible that the G-protein coupling of 6 -opioid receptors in brains of pKO mice are 
altered compared to wildtype in only some brain regions and that these small differences are 
responsible for the reported altered pharmacological responses.
This apparent conflict in the literature regarding the coupling of the 6 -opioid receptor in 
pKO animals can be explained by the different methodologies used in the studies. It has 
been shown both in the current study (see Chapter 2) and in previous studies (Sivam et ah, 
1981) that small but significant changes in receptor binding can be detected in discrete 
regions that are overlooked in whole brain membrane homogenate binding. In order to 
further characterise the 6 -opioid receptor ejq^ression and coupling throu^out the brains 
of pKO animals, quantitative autoradiographic studies of the 6 -opioid receptor in the 
brains of wildtype (+/+), heterozygous (+/-) and homozygous (-/-) mice for the p.- 
opioid receptor were completed in the presence and absence of GMPPNP.
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4.2 Materials and Methods
4.2.1. Animals
Knockout mice were generated in the laboratory of Professor Brigitte Kieffer in the 
Department of Molecular and Structural Pharmacology, Université Louis Pasteur, 
Strasbourg, France. p-Opioid receptor gene knockout animals were prepared according 
to the methods described by Matthes et ah (1996). Gene knockout was achieved by 
insertion of a neomycin cassette into exon 2 of the p-opioid receptor gene. Wildtype 
(+/+), heterozygote (+/-) and homozygote (-/-) mice were killed by decapitation and 
intact whole brains were removed, frozen and stored as detailed in Section (2.2.2.S.).
4.2.2. Brain Sectioning
Brains were stored at -70°C (for a maximum period of one month) before sectioning. 
Coronal brain sections (20pm) were cut at a 300pm interval from the olfactory bulbs 
through to the pontine nucleus in a cryostat (Zeiss Microm 505E) at -20°C. Adjacent 
sections were thaw mounted onto ice cold gelatin coated slides (see section 2 .2 .2 .2 .) for 
the determination of total binding, binding in the presence of GMPPNP (50pM) and 
non-specific binding (NSB) (determined by naloxone (lOpM)) for each of 
[^H]deltorphin I, RATGLU, [^H]SNC-121 and [^Hjnaltrindole. After sectioning
brains were stored as detailed in Section 2.2.2.4.
4.2.3. Radioligand binding
Sections from individual +/+, +/- and -/- mouse brains were processed together using 
identical radioligand stocks. Radioligandbinding, drying and storage was carried out as 
detailed in section 2 .2 .2 .5.1. except that only the highest concentrations of 
[^Hjnaltrindole (InM) and [^HJRATGLU (8 nM) was used.
After the dehydration period (Drierite in a sealed plastic container for a minimum of 5 
days) the sections were apposed to autoradiographic film (as detailed in Section 
2.2.2.6 .). For each [^H]0-opioid ligand, brain sections for total binding, binding in the
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presence of GMPPNP and NSB from +/+, +/- and -/- animals were placed in a single 
cassette. All films were apposed for 5 weeks before being developed (see Section 
2 .2 .2 .? .).
4.2.4. Image analvsis of autoradio graphic films
Quantitative analysis of autoradiographic films was carried out using video-based 
computerised densitometry employing an MCID image analyser (Imaging Research, 
Canada). Receptor binding was expressed as fmol/mg tissue equivalent as determined by 
reference to [^H]microscale standards see Section 2.2.2.6. Control specific binding and 
specific binding in the presence of GMPPNP was determined by subtraction of either 
total binding or binding in the presence of GMPNP (respectively) from NSB.
Measures were taken from both left and right hand sides of the brain for most structures 
and individual values are therefore a duplicate measurement. Central brain regions such 
as the thalamus and hypothalamus were measured singularly utilising a free hand 
sampling tool. All other regions were sampled using a box tool with a box size of 
8 x8 pixels, with the exception of the following regions; layers of the olfactory bulbs (box 
size 5x5pixels) and olfactory tubercle (box size 6 x6 pixels). For each film analysed, 
regions were quantified at the same level of the brain by reference to Bregma co­
ordinates used in the mouse brain atlas of Franklin and Paxinos (1997).
4.2.5. Data analysis and statistical procedures
For each [^H]6 -opioid ligand, a value for the mean specific binding (± S.E.M.) was 
determined for all brain structures analysed for both treatment groups (control specific 
binding and specific binding in the presence of GMPPNP) for +/+, +/- and -/- mice. The 
percentage change in binding in the presence of GMPPNP from control specific binding 
was also determined for all ligands in both +/+ and -/- brain sections. The percentage 
change in control specific binding of [^H]deltorphin I in -/- compared to +/+ animals was 
also determined. For statistical purposes, regions were split into cortical and non-
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cortical subsets before comparison of receptor binding was made using three factor 
analysis of variance (ANOVA) for the factors genotype, treatment and region. The 
effect of genotype on either the 6 -opioid control specific binding or binding in the 
presence of GMPPNP was determined using one way analysis of variance followed by 
Scheffe’s post hoc test.
4.2.6. Materials 
See Section 2.2.3.
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4.3. Results
4.3.1. Control specific binding
6 -Opioid receptors labelled with [^H]deltorphin I, pHJRATGLU, [^H]SNC-121 or 
[^HJnaltrindole were observed throughout the brain of wildtype (+/+) animals. The 
qualitative distribution of the 6 -opioid receptors was identical when labelled by the 
different radioligands (Figs. 4.1., 4.4., 4.7. and 4.10.). The NSB for both [^H]SNC-121 
and [^H]naltrindole was higher than that for either [^H]deltorphin I or [^H]RATGLU. 
Control specific binding (defined total binding minus NSB) in regions that expressed 
highest levels of binding of each [^H]6 -opioid ligand (external plexiform layer of the 
olfactory bulbs and lateral caudate) were as follows; [^H]deltorphin I >80%, 
[^H]RATGLU >70%, [^H]SNC-121 30-50% and pH]naltrindole 35-55%. The NSB for 
pH]SNC-121 (determined in the presence of lOjiM naloxone) showed regional 
differences in density. The qualitative distribution of this pH] SNC-121 residual binding 
was localised to regions showing high levels of 6 -opioid receptor expression (Fig. 4.13.).
Throughout the brain pH]SNC-121 and [^H]naltrindole control specific binding was 
consistently lower than [^H]deltorphin I or pH]RATGLU control specific binding 
(Tables 4.1. to 4.4. ). The densest binding of the pH]6 -opioid ligands was apparent in 
the external plexiform layer of the olfactory bulbs. Binding was also dense in the 
olfactory tubercle, lateral caudate putamen, the basolateral amygdala nucleus and the 
motor, visual, auditory, somatosensory and perirhinal cortices. (Tables 4.2 to 4.5.).
Moderate to high levels of control specific binding were detected in the shell division of 
the nucleus accumbens, the retrosplenial and entorhinal cortex, the superficial layer of 
the cingulate cortex and the pontine. Intermediate levels of control specific binding of 
the ligands were seen in the medial septum, basomedial and medial amgydala nuclei, 
hippocampus and stria terminalis. Low levels of control specific binding were observed 
in regions including the lateral septum, globus pallidus, interpeduncular nucleus, 
hypothalamus and thalamus (Tables 4.2. to 4.5.).
121
4.3.2. Effect of GMPPNP on control specific binding
The distribution of binding of all of the [^H]5-opioid ligands was unchanged in the 
presence of GMPPNP (50p.M) compared to control specific binding (Figs. 4.1., 4.4., 
4.7. and 4.10.). However, GMPPNP significantly reduced the level of binding of both 
[^H]deltorphin I and pH] SNC-121 in all brain regions quantified (3 way ANOVA 
P<0.01 for the factor treatment). The effect of GMPPNP on pH]SNC-121 binding was 
greater than the effect of [^H]deltorphin I binding (80% reduction in pH]SNC-121 
binding compared to 50% reduction in pH]deltorphin I binding) (Figs 4.1. to 4.6., Table 
4.1 and 4.2.). In contrast, pH]Naltrindole binding was significantly increased by the 
inclusion of GMPPNP in the incubation buffer in all brain regions analysed (3 way 
ANOVA P<0.01, for the factor treatment) (Fig 4.8. and Table 4.5.). GMPPNP did not 
significantly effect the binding of [^H]RATGLU binding to non-cortical regions, but 
GMPPNP did cause a significant decrease in binding in cortical regions (3 way ANOVA 
P<0.01 for the factor treatment) (Table 4.4.).
There was a significant interaction between region and the effect of GMPPNP on 
control specific binding of pH]SNC-121 (P<0.01), pH]naltrindole (P<0.01) and 
[^H]deltorphin I (P<0.05) in non-cortical regions (3 way ANOVA for the factors 
treatment and region). In cortical regions only pH]deltorphin I and pH]SNC-121 
showed a significant interaction between region and the effect of GMPPNP on control 
specific binding (3 way ANOVA, P<0.01 for the factors treatment and region).
4.3.3. Effect of genotvpe on control specific binding
The qualitative distribution of binding of all of the [^H]5-opioid ligands to 5-opioid 
receptors was identical in +/+, heterozygous (+/-) and homozygous (-/-) p.-opioid 
receptor knockout mice. Some individual regions showed a decrease in [^H]deltorphin I 
binding in +/- and -/- brains compared to +/+ brains (Table 4.2.), for example the core 
divisions of the nucleus accumbens (15% loss in +/- and 40% loss in -/- animals 
compared to +/+). Other regions showing a similar loss included the shell division of the
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nucleus accumbens (loss of 17% in +/- and 40% in lateral caudate putamen (loss of 
8 % in +/- and 1 1 % in thalamus ( 1 0 % in +/- and 15% loss in hypothalamus (loss 
of 23% in +/- and 25% in basolateral amygdala (loss of 6 % in +/- and 21% in -/-) 
and entorhinal cortex (loss of 16% in +/- and 23% in Genotype was shown to have 
a significant effect on the binding of pH]deltorphin I in non-cortical regions but not 
cortical regions (3 way ANOVA, P<0.01 for the factor genotype). One way ANOVA, 
followed by Scheffe’s post hoc analysis showed there was a significant down regulation 
of [^H]deltorphin I binding in -/- animals compared to +/+ in only one region, the 
hypothalamus.
In contrast to the findings with [^H]deltorphin I, the control specific binding of 
[^H]RATGLU binding was more variable in -/- compared to +/+ mice, some individual 
regions showed a decrease in binding whilst some showed an increase (Table 4.4.). 
Genotype was shown to have a significant effect on the binding of [^H]RATGLU in 
cortical regions but not non-cortical regions (3 way ANOVA, P<0.01 for the factor 
genotype). The binding of pH]RATGLU to cortical regions tended to be increased in 
both +/- and -/- compared to +/+ mice.
Genotype had a significant effect on the binding of pH] SNC-121 in non-cortical brain 
regions (3 way ANOVA, P<0.01 for the factor genotype) but not in cortical regions. 
pH] SNC-121 binding in non-cortical regions tended to be increased in -/- mice compared 
to +/+ for example in the external plexiform layer of the olfactory bulb (28%increase), 
tubercle (15%increase) and basolateral amgydala nucleus (5% increase) (Table 4.3.). 
There was no pattern in the change of pH]SNC-121 binding in +/- compared to +/+ 
mice.
[^H]Naltrindole control specific binding was increased in some regions in -/- and +/- 
compared to +/+ mice. These regions included tubercle (increase of 8 % in +/- and 20% 
in -/-), lateral caudate putamen (increase of 28% in +/- and 17% in -/-), and the
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Table 4.1. Three way ANOVA of pH]5-opioid receptor ligands binding for the factors 
genotype, region and treatment
Non-cortex Cortex
pH]Deltorphin I F-Ratio P Value F-Ratio P Value
Genotype 8.3 <0 . 0 1 2.37 N.S.
Region 361.4 <0 . 0 1 18.0 <0 . 0 1
Treatment 800.6 <0 . 0 1 1524.1 <0 . 0 1
Genotype x Region 1.5 N.S. 0.5 N.S.
Genotype x Treatment 6 . 1 <0.05 0.3 N.S.
Region x Treatment 33.1 <0.05 4.1 <0 . 0 1
Genotype x Region x Treatment 0.7 N.S. 0.3 N.S.
[^H]SNC-121
Genotype 3.8 <0.05 2.3 N.S.
Region 39.7 <0 . 0 1 3.9 <0 . 0 1
Treatment 133.3 <0 . 0 1 1873.8 <0 . 0 1
Genotype x Region 0.9 N.S. 1.06 N.S.
Genotype x Treatment 1 . 6 N.S. 2 . 2 N.S.
Region x Treatment 25.7 <0 . 0 1 3.4 <0 . 0 1
Genotype x Region x Treatment 0.4 N.S. 0.4 N.S.
[^H]RATGLU
Genotype 2 . 1 N.S. 7.5 <0 . 0 1
Region 310.2 <0 . 0 1 19.7 <0 . 0 1
Treatment 0 . 0 1 N.S. 56.1 <0 . 0 1
Genotype x Region 1 . 1 N.S. 0.7 N.S.
Genotype x Treatment 0 . 6 N.S. 2.4 N.S.
Region x Treatment 1.3 N.S. 1.4 N.S.
Genotype X Region x Treatment 0.3 N.S. 0.4 N.S.
pH]Naltrindole
Genotype 0.9 N.S. 3.9 <0.05
Region 116.2 <0 . 0 1 2 . 0 <0.05
Treatment 262.2 <0 . 0 1 89.5 <0 . 0 1
Genotype x Region 0 . 8 N.S. 0.4 N.S.
Genotype x Treatment 6 . 8 <0 . 0 1 2.4 N.S.
Region x Treatment 10.3 <0 . 0 1 0 . 2 N.S.
Genotype x Region x Treatment 0.7 N.S. 0.53 N.S.
N.S., not significant.
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basolateral amgydala (increase of 11% in +/- and 65% in deep visual (increase of 
15% in +/- and 43% in -/-) and superficial caudal somatosensory cortices (increase of 
22% in +/- and 36% in Genotype was shown to have a significant effect on the 
binding of [^H]naltrindole in cortical regions but not non-cortical regions (3 way 
ANOVA, P<0.01 for the factor genotype).
One way ANOVA, followed by Scheffespost hoc analysis failed to show a significant 
effect of genotype on the binding of pH]SNC-121, pH]naltrindole or pH]RATGLU in 
any individual regions.
4.3.4. Effect of genotvpe and GMPPNP on control specific binding 
The effect of GMPPNP (50pM) on control specific binding of [^ H] deltorphin I, 
pH]SNC-121, pH]RATGLU and pH]naltrindole was similar in +/+, +/- and -/- animals 
(Figs. 4.1. to 4.12., Table 4.2. to 4.5.).
There was a smaller percentage change in pH]deltorphin I binding induced by GMPPNP 
in some regions in -/- mice compared to +/+ mice. This difference was most marked in 
non-cortical regions and in regions that had a decreased level of binding in -/- mice 
compared to +/+ mice (Figs 4.2 and Fig. 4.3.). Regions that showed both a smaller 
percentage change in the effect of GMPPNP and decreased binding in -/- compared to 
+/+, include the shell and core divisions of the nucleus accumbens, tubercle, lateral 
caudate, thalamus, basolateral amygdala, hypothalamus and entorhinal cortex. Only two 
regions showed a greater percentage change of pH] deltorphin I binding induced by 
GMPPNP in -/- compared to +/+ mice, these regions were the interpeduncular nucleus 
and the pontine mice (Fig 4.2. and 4.3.). There was a significant interaction between the 
genotype and the effect of GMPPNP on the binding of pH]deltorphin I in both cortical 
and non-cortical regions (3way ANOVA for the factors treatment and region).
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In regions that did not express low pH] SNC-121 control binding there was a similar 
pattern of decreases in GMPPNP induced percentage changes in -/- mice compared to 
+/+ mice as seen with [^H]deltorphin I (Table 4.3 and Figs. 4.5. and 4.6.). Such regions 
included both the core and shell divisions of the nucleus accumbens, the tubercle, lateral 
caudate putamen, hypothalamus and entorhinal cortex. In the pontine GMPPNP was 
shown to induce a greater percentage decrease in the binding pH] SNC-121 in -/- 
compared to +/+ mice. In the basolateral amygdala there was a notable difference in the 
of the effect of GMPPNP on the binding of [^H]deltorphin I and pH]SNC-121 in -/- 
compared to +/+ mice. Binding of [^H]deltorphin I was increased whilst pH]SNC-121 
binding was decreased in -/- compared to +/+ mice (Figs. 4.3. and 4.6.). In agreement 
with the [^H]deltorphin I data, there was a significant interaction between genotype and 
the effect of GMPPNP on the binding pH]SNC-121 in both cortical and non cortical 
regions (3 way ANOVA, P<0.01 for the factors treatment and genotype).
There was a significant interaction between genotype and the effect of GMPPNP on the 
binding of [^H]naltrindole in non cortical but not cortical regions (3 way ANOVA, 
P<0.01 for the factors treatment and genotype). In agreement with the findings of both 
[^H]deltorphin I and pH]SNC-121, some regions showed a smaller percentage increase 
in [^H]naltrindole binding induced by GMPPNP in -/- mice compared to +/+. Such 
regions included the shell and core divisions of the nucleus accumbens, the basomedial 
amygdala, hypothalamus, hippocampus and medial and lateral caudate putamen.
There was no significant interaction between genotype and treatment on the binding of 
[^H]RATGLU in either cortical or non-cortical regions (3 way ANOVA, P<0.01 for the 
factors treatment and genotype).
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4.4. Discussion
4.4.1. Control Binding in wildtvpe animals
The distribution of [^H]deltoiphin I control specific binding in the brains of wildtype 
mice in the current study agrees closely with findings from earlier studies (Kitchen et al,
1997). Deltorphin I has been suggested to activate both the putative 5i and 6 2  receptor 
subtypes (Qian et al, 1996; Bilsky et a l, 2000), whereas naltrindole has been reported to 
have greater selectivity for the proposed 8 2  opioid receptor subtype (Sofuoglu et al, 
1991a). The selectivity of SNC-121 and RATGLU for the proposed 8 -opioid receptor 
subtypes has not been fully characterised to date. However, the parent compounds of 
each have been studied, deltorphin II (see Fig. 1.2. for relationship to RATGLU) has been 
suggested to be 8 2  opioid receptor subtype selective. In contrast SNC-80 (see Fig. 1.3. for 
relationship to SNC-121) has been suggested to have no selectivity over 8 1  and 8 2 -opioid 
receptors (Bilsky et al, 1995). Despite the proposed greater selectivities of 
[^H]naltrindole and possibly [^H]RATGLU for the putative 8 2  opioid receptor, there was 
no evidence from the current study of a different regional distribution of the binding of 
any of the [^H]8 -opioid ligands. This finding is in contrast to a previous study, which 
reported regional differences in the expression of 8 1  and 8 2 -opioid receptors (Hiller et al, 
1995). They reported binding of the putative 8 2 -opioid selective agonist [^H]DSLET 
exceeded the binding of the 8 1 -opioid selective agonist pH]DPDPE in areas such as basal 
ganglia, amygdaloid nuclei, hippocampus, hypothalamus and cerebral cortex. In contrast, 
other regions did not show significant differences in the binding of the two ligands. The 
regions that demonstrated higher levels of [^H]DSLET binding compared to pH]DPDPE 
are regions that have been previously reported to express high levels of other opioid 
receptors, notably the p,-opioid receptor (Kitchen et al, 1997). DSLET is known to have 
considerable affinity at p.-opioid receptors (Chang and Cuatrecasas, 1979; Gacel et a l, 
1980). This therefore raises the possibility that the increased number of sites recognised 
by DSLET compared to DPDPE is not due to the existence of 8 -opioid receptor subtypes 
but is due to DSLET recognising both p- and 8 -opioid receptors.
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Specific binding of both [^H]naltrindole and [^H] SNC-121 was relatively low 
(approximately 50%) as has been previously reported (Yamamurae/ a/., 1992; Ni et al, 
1995). Further to the results discussed in chapter 2, the residual [^H]SNC-121 (50-70% 
of total binding) appeared to be localised to the regions normally expressing the 5-opioid 
receptor (see Fig. 4.9.), such as the caudate, nucleus accumbens and cortical regions. 
Again, it is possible that either a different antagonist or pre-incubation with, or a higher 
concentration of, naloxone is needed to fully displace the [^H]SNC-121 binding from the
5-opioid receptor.
4.4.2. Effect of GMPPNP on binding in wildtvpe animals
There was an overall trend (>90% of regions analysed) in the effect of GMPPNP on 
either [^H]naltrindole, [^H]deltorphin I or [^ H] SNC-121 binding in wildtype brains, with 
either a decrease ([^H]deltorphin I and pH]SNC-121) or an increase ([^HJnaltrindole) in 
binding been seen in most regions. One notable differences to this was the globus pallidus 
where GMPPNP had reduced effect on the binding of any of the ligands compared to 
other regions. This finding may suggest that the 5-opioid receptors in the globus pallidus 
are not functionally coupled to G-proteins. There was a significant interaction between 
region and the effect of GMPPNP in both cortical and non-cortical regions for 
[^H]deltorphin I and [^H]SNC-121. Furthermore, GMPPNP induced a significant 
decrease in [^H]RATGLU binding in cortical but not non-cortical regions. Together these 
findings could suggest a regional difference in the coupling efficiency of the 5-opioid 
receptor, as has been previously reported for the p-opioid receptor (Maher et a l, 2000). 
Alternatively, it is known that 5-opioid receptors couple to multiple G-proteins (for a 
review see Quock et al, 1999)) and that there is a regional difference in which G-proteins 
are expressed (Wekesa and Anholt, 1999), this finding could therefore be due to a regional 
variation in which G-protein is coupled to the 5-opioid receptor. Different regional 
coupling of a receptor may result in small conformational changes in the receptor that may 
influence receptor binding.
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4.4.3. Control binding in pKO animals
In agreement with other studies, there were no major compensatory changes in the 
expression of the 6-opioid receptor in the brains of p-opioid receptor knockout mice 
compared to wildtype (Matthes et ah, 1996; Kitchen et al , 1997; Loh et al ,  1998; Chen 
et al , 2000). However, there was a significant interaction between genotype and binding 
of [^H]deltorphin I and [^Hjnaltrindole. In support of the findings of a previous study 
(Kitchen et al ,  1997), small but significant down regulation of [^H]deltorphin I binding 
was apparent in some regions of the brains of p-opioid receptor knockout compared to 
wildtype mice. There was a close agreement across the two studies with the regions 
demonstrating this down regulation, and indeed the level of the down regulation was 
shown to be similar. There was a similar but reverse trend in the binding of 
[^HJnaltrindole binding. Several regions demonstrated an upregulation of [^Hjnaltrindole 
binding but showed a decrease in binding of [^H]deltorphin I in -/- and +!- compared to 
+/+ mice brains. Considering the selectivities of [^H]deltorphin I and [^Hjnaltrindole for 
the coupled and uncoupled (respectively) 6-opioid receptor (Chapter 2 and 3), these 
finding suggest that some of the 6-opioid receptors become uncoupled from their 
associated G-proteins in the absence of the p-opioid receptor in some regions of the brain. 
This finding would explain the previously reported partial loss of 6-opioid agonist 
activity in pKO mice (Matthes et al , 1998; Hosohata et al ,  2000; Sora et al., 1997). This 
finding is in agreement with the recent report by Park et al, (2000) but in contrast to 
some earlier studies that suggest removal of the p-opioid receptor does not influence the
6-opioid receptor coupling (Matthes et al, 1998; Hosohata et al , 2000). However as 
previously mentioned, the methodology employed in the current study is known to be 
more sensitive to discrete changes in receptor coupling than the homogenate binding used 
by both Matthes (1998) and Hosohata (2000).
A physical interaction between the p -  and 6-opioid receptor has been postulated for
several years (Rothman and Westfall, 1982; Vaught eCûf/., 1982; Rothman et a l, 1988).
Receptor dimerization of opioid receptors has recently been demonstated to influence
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ligandbinding and pharmacological properties of ligands (Cvejic and Devi, 1997; Jordan 
and Devi, 1999). It is therefore feasible that if some 8-opioid receptors do exist as 
heterodimers with p-opioid receptors in vivo, that the removal of the p-opioid receptor 
from the complex could cause uncoupling of the 8-opioid receptor. It is of interest to note 
that only some regions demonstrate this proposed partial uncoupling of the 8-opioid 
receptor. Many of these regions have been previously reported to have a high level of p- 
opioid receptor binding (Kitchen et al, 1997). In agreement with the finding of only 
partial uncoupling of the 8-opioid receptor in pKO animals is the functional data which 
shows only a partial loss of some of the responses to 8-opioid agonists (Matthes et al.,
1998). However, in contrast to this are reports that there is no DPDPE induced analgesia 
(hot plate and tail flick) (Sora et al., 1997) or DPDPE induced GTPyS activation (Park et 
al., 2000) in pKO animals.
If partial uncoupling of some of the 8-opioid receptors is responsible for the changes 
observed in pKO mice, it would be expected that the binding of 8-opioid ligands with a 
greater selectivity for either the coupled or uncoupled receptor states would show these 
changes, whereas ligands without selectivity would be unaffected; In agreement with this 
hypothesis, there is no significant interaction between genotype and binding of 
[^H]RATGLU (equal affinity for both states, see Chapter 2). In contrast the [^H]SNC- 
121 binding data does not support this theory, despite the greater selectivity of pH] SNC- 
121 for the coupled 8-opioid receptor state (Chapter 2) the overall trend is for binding in - 
/- mice to be greater than in +/+ mice. pH] SNC-121 is known to have an atypical binding 
interaction with the 8-opioid receptor (Li et al., 1995), it is feasible that is responsible for 
the anomalous result compared to the other ligands.
4.4.4. The effect of GMPPNP on the binding in jiiKO mice
Further support for there being a region dependent uncoupling of 8-opioid receptor in the 
absence of the p.-opioid receptor is provided by the significant interaction between the 
effect of GMPPNP and genotype on the binding of [^H]deltorphin I and [^H]naltrindole.
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Chapter 5
Characterisation of the binding of [^H]SNC-121 and 
pH] deltorphin I in brains of mice lacking the 6-opioid
receptor.
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5.1. Introduction
The first report of the generation of mice lacking the 5-opioid receptor gene (5K0) was 
made by Zhu et al, (1997). In the 3 years since this initial report there have been just two 
full papers on 5K0 mice (Zhu et al, 1999; Filliol et al, 2000). Both groups utilised 
homologous recombination to generate the ÔKO mice but targeted a different exon. Exon 1 
of the 5-opioid receptor gene was targeted by Filliol et al (2000) whilst Zhu et al, (1999) 
targeted exon 2. No gross anatomical deficits were apparent in the animals and normal 
development, weight gain and reproduction have been reported (Zhu et a l, 1999; Filliol 
gf a/., 2000).
Binding of both 5i-and 02-opioid receptor ligands i.e. pHJDPDPE (5i), pH]deltorphin II 
(Ô2), [^H]deltorphin I (Ô2) and [^H]naltrindole (5i and Ô2) were shown to be at the level of 
the non-specific binding in 5K0 mice brain membranes. This finding confirms the 
successful deletion of the 5-opioid receptor and suggests that the 5-opioid receptor gene 
encodes both of the proposed 5-opioid receptor subtypes (Zhu et a l, 1999; Filliol et a l, 
2000). Overall there were no major compensatory changes in the expression of the other 
opioid receptors in the brains of ôKO mice (Zhu et al, 1999; Filliol et al, 2000). Similarly 
the expression of mRNA encoding for the endogenous opioid peptide precursors was 
shown to be unchanged in the brains of 5K0 mice compared to wildtype (Filliol et a l, 
2000). Together these finding suggest that there are no major compensatory changes in the 
opioid system in 5K0 mice.
In contrast to wildtype, ÔKO mice have been shown not to have altered baseline latencies in 
the tail flick model. The antinociceptive responses to both deltorphin II and DPDPE 
following intrathecal injection were attenuated in ÔKO mice. In contrast to this finding, 
antinociceptive responses to both DPDPE and deltorphin II were retained following 
intracerebroventricular (i.c.v.) injection (Zhu et a l, 1999). Intrathecal injection of the non­
peptide 5-opioid agonist BW373U86 was shown not to elicit analgesic action in wildtype or 
ÔKO mice. In contrast i.c.v. injection of BW373U86 was shown to be a potent analgesic in
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ÔKO mice but not wildtype mice. It was proposed from these findings that 0-opioid 
receptor agonists mediate spinal antinociception through the ô-opioid receptor, but that an 
alternative pathway exists for the supraspinal antinociception (Zhu et a l, 1999). The 
DPDPE induced antinociception in ÔKO mice was shown to naltrexone reversible. In 
contrast the p.-opioid receptor antagonist P-funaltrexamine and the K-opioid receptor 
antagonist norbinaltorphimine did not block DPDPE induced antinociception in ÔKO mice. 
Furthermore the 5-opioid receptor antagonist naltrindole only partially reduced DPDPE- 
induced antinociception in 5K0 mice (Zhu et al, 1999). Together these results suggest that 
DPDPE induced antinociception in 5K0 animals via an opioid mechanism that is not 
through the classical 5, |i or K-opioid receptors.
5K0 mice have also been shown to not develop tolerance after chronic morphine treatment 
(Zhu et al, 1999). This finding confirms genetically that 5-opioid receptors are critically 
involved in the development of tolerance after chronic morphine treatment. This finding is 
in support of previous pharmacological results which suggest the involvement of 5-opioid 
receptors in the development of tolerance after chronic morphine treatment (Abdelhamid et 
al, 1991).
In a recent study 5K0 mice have been shown to have increased locomotor activity under 
non-stressful conditions (Filliol et al, 2000). 5K0 mice have also been reported to show 
elevated anxiety levels in both the elevated plus maze and the light-dark box. In 
behavioural models of depression 5K0 mice were shown to demonstrate greater depressive 
like behaviour than wildtype animals (Filliol et a l, 2000). The authors propose from these 
studies that 5-opioid receptors are involved in mood states and that this may be a potential 
target for drug development.
A recent autoradiography study from our laboratory (Goody, 2000) has demonstrated 
residual [^H]deltorphin I binding above the level of NSB in the brains of 5K0 mice 
following 12 week film exposure. The regions expressing this residual binding had a
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significant correlation with areas reported to express high levels of p-opioid receptors 
(Goody, 2000; Kitchen et al., 1997). In order to further address this issue this study will 
determine the binding of [^H]deltorphin I in the presence and absence of DAMGO (a p- 
opioid receptor agonist) in the brains of ôKO mice.
As previously discussed SNC-121 has an atypical binding profile at the Ô-opioid receptor 
(Chapter 2 and 4). In the presence of excess naloxone residual SNC-121 binding is 
localised to areas normally expressing high levels of ô-opioid receptors. [^H]SNC-121 
binding has been shown not to bind to a  or P-adrenoceptors, dopamine receptors (Di or 
D]), muscarinic receptors, or adenosine (Ai) receptors. However the presence of 
thioperamide and verapamil has been shown to decrease the binding of [^H]SNC-121 
(personal communication Dr. W. Richards, Pfizer Central Research, Kent). In order to 
further characterise the residual [^H]SNC-121 binding an autoradiographic study in the 
brains of 5K0 mice was carried out.
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5.2 Materials and Methods
5.2.1. Animals
Knockout mice were generated in the laboratory of Professor Brigitte Kieffer in the 
Department of Molecular and Structural Pharmacology, Université Louis Pasteur, 
Strasbourg, France. 5-Opioid receptor gene knockout animals were prepared according 
to the methods described by Filliol et al. (2000). Gene knockout was achieved by 
insertion of a neomycin cassette into exon 1 of the 5-opioid receptor gene. Wildtype 
(+/+), heterozygote (+/-) and homozygote (-/-) mice were killed by decapitation and 
intact whole brains removed, frozen and stored as detailed in Section (2.2.2.3.).
5.2.2. Brain Sectioning
For brain sectioning see Section 4.2.2. Adjacent sections from either ÔKO +/+ or -/- 
mice were thaw mounted onto ice cold gelatin coated slides (see section 2.2.2.2.) for the 
determination of total [^H] SNC-121 binding, [^H] SNC-121 binding in the presence of 
naloxone (lOpM), naloxone (lOpM) and verapamil (lOpM), naloxone (lOpM) and 
thioperamide (lOpM) or naloxone, thioperamide and verapamil (all at lOpM). In 
addition adjacent sections from both 5K0 +/+ and -/- mice brains were cut for the 
determination of total [^H] deltorphin I binding, [^ H] deltorphin I binding in the presence 
of DAMGO (IpM) and non-specific binding (determined by naloxone (lOpM). After 
sectioning brains were stored as detailed in Section 2.2.2.4.
5.2.3. Radioligandbinding
Sections from individual +/+ and -/- mouse brains were processed together using 
identical radioligand stocks. Radioligand binding, drying and storage was carried out as 
detailed in section 2.2.2.5.1.
After the dehydration period (Drierite in a sealed plastic container for a minimum of 5 
days) the sections were apposed to autoradiographic film (as detailed in Section
2.2.2.Ô.). For each [^H]5-opioid ligand, brain sections for all treatment groups from both
166
+/+ and -/- animals were placed in a single cassette. Films of SNC-121 binding were 
apposed for 5 weeks whereas films of [^H]deltorphin I binding were apposed for 12 
weeks before being developed (see Section 222.1.).
5.2.5. Data analvsis
Qualitative analysis of binding of [^H]deltorphin I and [^H] SNC-121 was used. 
Comparison of the density and regional distribution of the binding of both ligands were 
made in +/+ and -/- mice for all treatment groups.
5.2.6. Materials
See Section 2.2.3. Thioperamide and verapamil were purchased from Sigma and 
DAMGO was purchased from Bachem.
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5.3. Results
5.3.1. r^HIDeltorphhin I binding in 5K0 mice brains.
Residual [^H] deltorphin I binding was apparent throughout the brains of ÔKO (-/-) mice 
after 12 week exposure to [^H]sensitive autoradiographic film. The residual 
[^H]deltorphin I binding was displaced by either naloxone (lOpM) or DAMGO (IpM) 
(Fig. 5.1.).
5.3.2. f^ H1 SNC-121 binding in 6K0 mice brains.
There was a similar regional distribution in the binding of [^H] SNC-121 in the 
brains of wildtype and -/- ÔKO mice (Fig. 5.2. -  5.4.). The distribution of the SNC- 
121 binding was similar to the distribution of [^H]deltorphin I binding in the brains of 
wildtype mice. The binding of [^H]SNC-121 was denser in the brains of wildtype 
compared to -/- mice (Fig. 5.2. -  5.4.). In the presence of naloxone (lOpM) there was 
residual [^H]SNC-121 binding in both +/+ and -/- mice. The density of this residual 
[^H]SNC-121 binding was similar in both genotypes (Fig. 5.2. -  5.4.). In -/- mice there 
was not an apparent difference between the density of total [^H] SNC-121 binding and 
SNC-121 binding in the presence of naloxone (Fig. 5.2. -  5.4.). The localisation of 
the residual [^H] SNC-121 binding was predominantly in the areas normally expressing 
high levels of 5-opioid receptor (e.g. nucleus accumbens, hippocampus and cortical 
regions) (Fig. 5.2. -  5.4.). Binding of SNC-121 was also apparent in some regions 
which do not express high levels of 5-opioid receptors, including the interpeduncular 
nucleus and the stria terminalis (Fig. 5.2. -  5.4.). The inclusion of either thiopermide 
(lOpM) or verapamil (lOpM) together with naloxone (lOpM) decreased the density of the 
residual [^H]SNC-121 binding below the level of [^H]SNC-121 binding in the presence of 
naloxone alone (Fig. 5.2. -  5.4.). The inclusion of both thioperamide (lOpM), verapamil 
(lOjiM) with naloxone (lOpM) did not further decrease the residual binding of SNC-121
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(lOjjM) compared to the inclusion of either thioperamide or verapamil with naloxone 
alone (Fig. 5.2 - 5.4.).
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5.4. Discussion
Residual H]deltorphin I binding was observed in the brains of mice lacking the ô-opioid 
receptor after 12-week exposure to [^H] sensitive film. This binding was displaced by either 
naloxone or DAMGO. This finding suggests that [^H]deltorphin I labels an opioid site that 
is not encoded for by the 5-opioid receptor gene. The concentration of DAMGO used in 
this study to displace the [^H]deltorphin I binding and the previously demonstrated 
distribution of the [^H]deltorphin I binding in the brains of 5K0 mice (Goody, 2000). 
suggest that [^H]deltorphin (7nM) binds weakly to p-opioid receptors. This finding is in 
contrast with the proposed [^H]deltorphin I selectivity of more than 7000 fold for 5-opioid 
receptors over p-opioid receptors (Erspamer et a l, 1989). The presence of GMPPNP 
(50pM) was shown to decrease the residual [^H]deltorphin I binding. In binding (data not 
shown) which suggests that [^H]deltorphin I may behave as an agonist at p-opioid 
receptors.
The density of [^H] SNC-121 binding was reduced in the brains of -/- compared to +/+ 5K0 
mice. This finding confirms that SNC-121 binds to 5-opioid receptors. However, both 
+/+ and -/- 5K0 mice showed similar [^H]SNC-121 binding in the presence of naloxone. 
This finding suggests that the residual.[^H]SNC-121 binding in mice brains is not due to the 
atypical binding profile of [^H] SNC-121 to the 5-opioid receptor (see Chapter 2 and Li et 
al, 1992). [^H]SNC-121 therefore appears to bind to a receptor that is not an opioid
receptor, but that is largely localised to areas that normally express a high level of 5 -opioid 
receptors. Some areas demonstrating residual [^H]SNC-121 binding do not express a high 
level of 5 -opioid receptors including the interpeduncular nucleus and the stria terminalis, 
these regions have been previously demonstrated to express high levels of p-opioid 
receptors (Kitchen et al, 1997). Both thioperamide (Hg-receptor antagonist) and verapamil 
(Ca^  ^ channel antagonist) decreased the residual [^H]SNC-121 binding in -/- dKO mice 
brains in a similar manner. This effect was not additive, suggesting that they may be 
displacing [^H]SNC-121 binding from the same receptor. This finding would suggest that 
[^H] SNC-121 is not binding at either a calcium channel or a histamine receptor.
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It therefore remains unclear what is responsible for the residual [^H]SNC-121 binding. 
However this study has provided more evidence demonstrating what [^H] SNC-121 is not 
binding to. This study has provided evidence that the residual [^H]SNC-121 binding in the 
presence of naloxone is not through an opioid receptor, the ORL-1 receptor, a G-protein 
coupled receptor, a Hg-histamine receptor or a calcium channel (see Chapter 2 and 4). This 
study therefore extends the previously reported findings that the residual [^H]SNC-121 
binding is not mediated through dopamine, 5HT or a-opioid receptors (Ni et al., 1995). In 
addition to this finding it is of interest to note that a saturation curve to [^H] SNC-121 could 
not be constructed in the absence of peptidase inhibitors (Chapter 2). This finding was of 
some surprise due to the non-peptide nature of [^H]SNC-121. Together these findings 
suggest that it is possible that [^H] SNC-121 may bind to a peptide that is currently 
unidentified but is localised to areas that express the 5-opioid receptor. The existence of a 
protein associated with another receptor has recently been described (Lezcano et al, 2000). 
This study reported a 24Kdalton peptide (named calcyon) which interacts with the Dl 
dopamine receptor (Lezcano et al, 2000) and is involved in Ca^^-dependent signalling.
A question which needs to be addressed is whether the residual [^ H] SNC-121 binding is 
purely an interesting pharmacological curiosity or whether it is responsible for a functional 
response. It is interesting that some 5-opioid agonists retain some of their antinociceptive 
activities in mice lacking the 5-opioid receptor (Zhu et a l ,  1999). These responses have 
been demonstrated to be reversible by the non-selective opioid antagonist naltrexone but 
not by opioid receptor antagonists selective for each of the subtypes of the opioid receptors 
(Zhu et al , 1999). This finding suggests the response is not mediated through a classical 
opioid receptor. One of the compounds demonstrating this residual antinociception is 
BW373U86, a close analogue of SNC-121 (see Fig. 1.3) (Calderon et al , 1994; Calderon et 
al ,  1996). It is tempting to speculate that the atypical responses of 5-opioid receptor 
agonists in 5K0 mice may be related to the residual binding of [^H]SNC-121. Presently 
there is no evidence to confirm this suggestion, but it would be of interest to determine if 
SNC-121 produces residual antinociception in 5K0 mice, if the residual binding of
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[^H]SNC-121 was reversible by naltrexone and if the retained antinociception to 5-opioid 
agonists is reversible by naloxone.
It is clear from this work that [^H]deltorphin I does have a weak affinity for the p.-opioid 
receptor and that [^H]SNC-121 labels a site in mouse brain that is not a classical opioid 
receptor. The exact nature of this [^H] SNC-121 binding site remains unclear.
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CHAPTER 6
General discussion
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6. GENERAL DISCUSSION
From experiments utilising mice lacking the |i-opioid receptor the current study provides 
evidence that demonstrates some 5-opioid receptors become uncoupled from their G- 
proteins in the absence of the p.-opioid receptor. This finding provides further evidence to 
support the existence of a functional interaction between p- and 5-opioid receptors. The 
presence of opioid receptor heterodimers have been previously reported from studies 
utilising cell lines (Jordan et al., 1999). The present work extends these findings and 
suggests that heterodimers may also exist in vivo. Furthermore this study provides a 
feasible explanation for the data which reports a partial loss of some 5 -opioid receptor 
mediated responses in mice lacking the p-opioid receptor (Matthes et al , 1998; Sora et al,  
1997b). To further investigate the proposed p/5-opioid receptor complex it would be of 
interest to investigate the G-protein coupling of the p-opioid receptor in animals lacking the 
5-opioid receptor.
5-Opioid receptor subtypes have been postulated for many years (see Section 1.10). The 
cloning of genes encoding receptor subtypes or the identification of functional splice 
variants is the only definitive proof of the existence of receptor subtypes. Despite the 
pharmacological evidence supporting the existence of 5-opioid receptor subtypes only one 
gene has been discovered which encodes for 5-opioid receptors (Kieffer et al , 1992; Evans 
et al , 1992). It has been speculated that the data which supports the existence of 5-opioid 
receptor subtypes may be due to a different phenomenon. Promiscuously coupled 
receptors, the existence of homo and heterodimers and different receptor expression have 
all been suggested to be responsible for data that can be interpreted as proof of receptor 
subtypes (Jordan et al,  1999; Kenakin, 1995; Zemig et al , 1999). The work in this thesis 
demonstrates that the binding of 5-opioid receptor ligands which have been previously 
reported to have different affinities for the proposed 5-opioid receptor subtypes do not 
show regional differences in the distribution of binding in mouse brain. This study 
therefore provides no evidence to support the existence of 5-opioid receptor subtypes in 
mouse brain. Instead the results from these experiments demonstrate that differences in
182
the number of binding sites recognised by ligands may be due to ligands having different 
affinities for the coupled and uncoupled receptor states rather than recognition of different 
receptor subtypes.
This study consistently shows that the decrease in binding of the 6 -opioid receptor agonist 
[^HJdeltorphin I in the presence of either GMPPNP or sodium ions is due to a loss of 
binding sites and not due to a reduced affinity of the ligand for the receptor. This finding 
suggests that there must be at least three 6 -opioid receptor states. In common with other 
studies utilising a variety of G-protein coupled receptors (see Strange, 1997) the present 
study provides data which can not be explained using the Leff two state receptor model 
(1997). This finding suggests that an alternative receptor model (e.g. the extended ternary 
complex or the agonist induced multiple conformation model) should be used to explain 
data from studies investigating G-protein coupling of 6 -opioid receptors. The proposed 
third receptor state of the 6 -opioid receptors suggested by this study has not been 
characterised in this study and further work would be needed to determine the existence and 
the nature of this state. Recent evidence of agonist induced changes in the level of 
oligomerisation of receptors could be an explanation for the apparent change in receptor 
number in the presence of GMPPNP or sodium ions. It would be of interest to use real 
time evaluation of receptors labelled with flourescent proteins to try to determine the effect 
either GMPPNP or sodium ions have on the number of 6 -opioid receptors expressed on the 
plasma membrane.
The results from this thesis provide data that suggests naltrindole behaves as an inverse 
agonist at mouse and human 6 -opioid receptors. This finding is in contrast to other reports 
that demonstrate naltrindole behaves as either a partial agonist or a pure antagonist. The 
reported effects of naltrindole have been determined in a variety of systems and different 
assays. The work described in this thesis therefore provides further evidence to support the 
hypothesis that the effect of a ligand on a receptor is at least partially related to receptor 
expression and the system used (Clark et al, 1997).
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The binding of SNC-121 to 5-opioid receptors has been reported to be atypical compared to 
peptide 5-opioid receptor agonists. Furthermore SNC-121 has been proposed to bind to a 
site which is not an opioid receptor. This study demonstrates that in the brains of mice 
lacking the 5-opioid receptor, [^ H] SNC-121 binds to a site that is localised to brain regions 
which predominantly express high levels of 5-opioid receptors. This study therefore 
provides further evidence to support the existence of a non-opioid SNC-121 binding site 
and for the first time suggests that this site may be co-localised to areas of the brain 
normally expressing high levels of 5-opioid receptors. This study also shows that this 
SNC-121 binding site is not at the ORL-1 receptor, the H3 receptor or at L-type Ca^  ^
channels. In addition the SNC-121 binding site does not appear to be through a G-protein 
coupled receptor.
In conclusion the work that is included in this thesis has shown that both pharmacological 
manipulation of G-protein coupling of the 5-opioid receptor and removing the p-opioid 
receptor gene can influence the effect of both selective 5-opioid receptor agonists and 
antagonists.
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